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 Cancer metastasis is a multi-faceted process requiring the disregualtion of 
numerous signaling pathways, including those associated with cell adhesion and motility.  
Recent data indicates strongly that growth at a primary tumor site and growth at a 
metastatic site differ by the expression and/or context-dependent function of the 
metastasis regulator, and that a wide variety of signaling pathways are affected.  PTEN 
(phosphatase and tensin homologue deleted on chromosome ten) then becomes an 
attractive candidate for a metastasis suppressor, based on its ability to negatively regulate 
numerous pathways involved in cell survival, cell proliferation, and cell motility.  
Conversely, the Rho family of small GTPases have become attractive candidates as 
contributors to metastasis.  Rho GTPases regulate numerous signaling pathways involved 
in cell survival, cell proliferation and cell motility, but they function to enhance these 
processes instead of inhibiting them. 
 vii
 Data presented here demonstrates the ability of PTEN to negatively regulate 
motility in human metastatic breast cancer cells without causing the cells to undergo 
apoptosis.  PTEN is localized in stimulated cells away from the leading edge, which 
displaces it from sites of active motility signaling and prevents it from inhibiting these 
processes.  Furthermore, ectopic PTEN expression is shown to downregulate 
phosphoinositol (3,4,5) triphosphate (PIP3), expression.  Therefore, PTEN could be 
acting as a metastasis suppressor in human breast cancer. 
 Data presented here also demonstrate the ability of the Rac subfamily of Rho 
GTPases to enhance metastatic properties and contribute to metastasis.  Increased Rac 
activity was shown to correlate with increased metastatic potential in a panel of 
metastatic human breast cancer cell variants.  When activated Rac1 or Rac3 was 
expressed stably in the least metastatic variant, either isoform was found to enhance 
adhesion, migration, and invasion in vitro, as well as contribute to pulmonary metastasis 
in the nude mouse model of experimental metastasis.  Conversely, when dominant 
negative Rac1 or Rac3 was expressed in the most metastatic variant, either isoform was 
found to decrease adhesion, migration, and invasion in vitro, as well as block pulmonary 
metastasis in vivo.  Therefore, Rac1 and/or Rac3 are found to act as metastasis regulators 
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1.  Introduction 
 
1.1  Cancer 
 
 Cancer is a general term that describes a group of diseases characterized by 
uncontrolled cellular growth, or neoplastic transformation.  Neoplastic transformation is a 
multi-step process that requires multiple genetic changes.  If unchecked, neoplastic 
transformation can result in the formation of a tumor, or an abnormal mass of cells.   
Tumors have the potential not only to invade and destroy surrounding tissue, but also 
spread through the blood stream and establish secondary tumors at distant sites.  Because 
cancer can occur in most any tissue in the body, there are more than a hundred distinct 
types of this disease (Cooper and Hausman, 2004).  These cancer types can vary 
substantially in behavior, protein expression, and eventual response to treatment.  
However, the cells that comprise tumors share three basic biological properties: 
uncontrolled (density-independent) proliferation, impaired cellular differentiation, and 
invasiveness (Karp, 1999).  Recent research has revealed that all cancers share common 
molecular mechanisms governing these biological properties, and those molecular 
mechanisms have become the first line of attack in order to find treatments or cures for 





Oncogenes and Tumor Suppressors  
Because it can be traced to mutations within specific genes that lead to abnormal 
gene expression, cancer is considered a genetic disease.  Basically two types of genetic 
mutations are associated with oncogenic transformation:  gain of function or loss of 
function. Oncogenes are genes that are mutated in such a way as to cause gene product 
overexpression or hyperactivation (gain of function mutation).  These genes typically 
encode proteins important for cell cycle progression or cellular proliferation, and 
consequently cause cellular transformation and tumor formation when hyperactivated.    
Conversely, tumor suppressor genes encode proteins that negatively regulate cellular 
growth.  These genes are mutated in such a way as to inactivate, or incapacitate, the 
encoded protein (loss of function mutation).  As these proteins negatively regulate cell 
proliferation, loss of protein function can result in uncontrolled proliferation, or cellular 
transformation.  Generally, the more advanced a cancer is, the more genes that have been 
altered within the cells.  This observation renders cancer extremely difficult to treat for 
the reason that each tumor has its own profile of oncogene expression and tumor 
suppressor inactivation.  Essentially, each tumor is genetically unique and therefore will 
respond uniquely to different treatments.      
 
Causes of Cancer 
 A tumor that is invasive is referred to as a carcinoma, or cancer.  The causes of 
cancer can be divided into two groups:  exogenous (environmental factors) and 
endogenous (genetic predisposition).  Exogenous carcinogens cause sporadic cancers that 
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are caused by a cumulative series of somatic mutations acquired over the lifetime of the 
patient.  Hereditary cancers, or cancer predisposition syndromes, represent a type of 
tumor formed from a genetic mutation that is inherited.  However, inherited genetic 
alteration is rarely enough to cause tumors.  Disease is often presented only after 
exposure to environmental insults.   
 Carcinogenesis is thought to develop in two stages:  initiation and promotion.  
The first stage of carcinogenesis, or initiation, involves the mutation of nuclear DNA by a 
mutagen.  However, this mutation is not enough to cause uncontrolled cellular growth.  
The cell containing the mutation must then be unable to police the damaged DNA, and so 
replicate with no DNA repair.  The mutated cell must also lose the ability to control 
proliferation.  This latter stage is referred to as “promotion”, and requires repeated 
exposure of the cell to a promotion agent.  Tumor promoters do not cause tumorigenesis 
alone, but enhance tumor formation subsequent to mutagenesis.   
   
Breast Cancer 
Breast cancer is the leading type of cancer occurring in women in the US, and it 
affects almost one million women worldwide at any give time (Bowcock, 1999).  It is 
estimated that one in eight women will develop breast cancer, and of these women, 30% 
will die from metastatic progression (Bowcock, 1999).  The American Cancer Society 
predicts that in the year 2005, 40,000 women will die from this disease (ACS, 2005). 
 Breast cancer is a malignant tumor that has developed from the cells of the breast.  
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There are essentially three distinct structures that make up the female breast:  the lobules, 
or milk-producing glands; the ducts, or the passages that connect the lobules to the nipple 
and conduct milk during lactation; and the stroma, or the fatty and connective tissue that 
surrounds the ducts and lobules, blood vessels, and the lymphatics.  Nearly all breast 
cancers arise in either ductal tissue or lobular tissue, and are referred to as 
adenocarcinomas.  The most common diagnosis for aggressive breast cancer is Invasive 
Ductal Carcinoma (IDC).  This cancer has arisen from epithelial cells lining the milk 
ducts, but it has invaded into the wall of the duct itself.  This type of cancer will account 
for about 80% of  invasive breast cancer diagnoses (ACS, 2005).    
Studies have shown this high risk in part due to the structure and development of 
the mammary gland itself (Russo et al., 2001).  The breast undergoes dramatic changes in 
size, shape, and function, depending on growth, reproduction, and menopause (Russo et 
al., 2001).  Essentially, the breast was designed to fluctuate dramatically in size, 
rendering it more susceptible to uncontrolled proliferation than other organs that do not 
experience such turnover.  Interestingly, cancer risk appears to be related to the duration 
of the periods of homeostasis (Anderson, 2004).  Encouragingly, mortality from breast 
cancer is decreasing due to early detection (ACS, 2005).  However, metastatic disease 
almost always ends in death.  Therefore, focus must be realigned with breast cancer 





Incidence and Mortality Statistics 
 Cancer not only presents an interesting molecular mechanism challenge, but it 
also presents a terrible and debilitating disease.  In 2002, the American Cancer Society 
ranked cancer as the second leading cause of death, accounting for nearly 25% of all 
deaths in the United States (ACS, 2005).  By 2001, it was estimated that 1 in 2 men 
would be diagnosed with cancer in their lifetime, while those statistics are 1 in 3 for 
women (ACS, 2005).  Moreover, cancer has seen the least advancement in prevention 
and cure among the top four leading causes of death in the US in the last 50 years (ACS, 
2005). Clearly, cancer presents an acute problem with relatively slow success in 





 Tumors, or masses of cells resulting from uncontrolled cellular growth,  fall into 
two general categories:  benign and malignant.  Benign tumors place the patient a low 
risk, for they have not yet invaded the surrounding tissue and have a low probability of 
spreading throughout the body.  Malignant tumors, or carcinomas, have invaded the 
surrounding tissue and have a high probability of spread.  Whereas benign tumors can 
usually be removed surgically due to well-circumscribed borders and confinement to the 
original tissue, malignant tumors present more of a problem.  If the tumor has spread to 
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other parts of the body, surgery is usually not an option.  Treatment becomes more 
difficult, more dangerous, and mortality dramatically increases.     
 
Metastatic Progression 
Metastatic progression is the process by which cancer spreads throughout the 
body.  Cancer cells, migrating as individuals or as aggregates, actively migrate away 
from the primary tumor, invade through the surrounding extracellular matrix, and enter 
the blood stream.  These cells then are carried via the circulatory system to distant sites, 
where the cells exit the blood stream and form secondary tumors at these sites.  By 
definition, metastatic cells must have acquired more mutations than primary tumor cells.  
Metastatic cells must not only have acquired the ability to proliferate uncontrollably, but 
must have acquired the ability to actively migrate and invade into surrounding tissue.  In 
the case of most breast cancers, the tumor arises from well-differentiated, polarized 
epithelial cells.  The cells must undergo the epithelial to mesenchymal transition to 
acquire the ability to attain fibroblast-like motility and invasion needed for metastatic 
progression.  Consequently, metastatic cells must either acquire gain of function 
mutations in genes important for cell motility and invasion, or loss of function mutations 
in genes that negatively regulate these processes.      
 Surprisingly, only a few steps of metastasis are rate-limiting (Chambers et al., 
2002).  Studies have shown high numbers of cancer cells in the circulatory system of 
cancer patients as compared with the number of metastases in distant organs (Chambers 
et al., 2000).   Furthermore, cell survival in the circulation, arrest in distant organs, and 
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initial extravasation were found to be relatively efficient (Steeg et al., 2003).  However, 
the metastatic colonization of distant organs was shown to occur quite inefficiently, and 
appears to be the rate-limiting step of metastasis (Chambers et al., 2000).   
 
Metastasis Suppressors/Inhibitors 
 Recently, a class of genes labeled “metastasis suppressors” is beginning to gain 
attention.  They have been identified by reduced expression in metastatic tumors as 
compared to their primary, non-metastatic, counterparts (Steeg et al., 2003).  Metastasis 
suppressors appear to act at different steps of the metastatic process, and are not just 
limited to suppress the rate-limiting metastatic colonization (Steeg et al., 2003).  One of 
the first identified metastasis suppressors, NM23, has been shown to reduce 
Extracellular-Signal-Regulated-Kinase-Mitogen-Activated-Protein-Kinase (ERK) 
activation levels, as compared to controls (Steeg et al., 2003).  ERK is a member of the 
Mitogen Activated Protein (MAP) kinase family of serine-threonine kinases that initiate 
phosphorylation signaling cascades which eventually result in the initiation of cell 
proliferation (Rubinfeld and Seger, 2004).  Conversely, metastasis suppressor RhoGDI2 
(Rho Guanine Dissociation Inhibitor 2) acts on adhesion and motility pathways (Gildea et 
al., 2002).  Therefore, it is difficult to predict the efficacy of future metastasis suppressors 




1.3 Cell Motility 
 
 Metastatic progression is thought to be facilitated by cell motility.  Cell motility is 
a broad term that encompasses the migration of cells across a substrate, the ability of cells 
to make and break adhesions with the substrate across which they are moving, and 
invasion of cells within a three-dimensional matrix.  Most early work with mammalian 
cell motility was accomplished by observing cells crawl across two-dimensional 
substrates (usually coverslips), and this is how the process is best understood.  At its most 
basic, cell movement can be divided into three distinct steps:  extension of the leading 
edge, attachment of the leading edge to the substratum, and retraction of the rear of the 
cell (Alberts et al., 2002).  However, motility is a highly complex and intricately 
regulated process.  Different parts of the cell must change at the same time, and there is 
no single gene, set of genes, or apparatus responsible for mammalian cell migration 
(Alberts et al., 2002).  The most important protein regulating cell motility is actin, a 
highly abundant cellular protein that polymerizes to form cytoskeletal filaments.            
 
Actin 
Actin exists in cells as both globular (g-actin) and filamentous (f-actin).  G-actin 
polymerizes into filaments either spontaneously in vitro if monomer concentration and 
ionic strength is optimal, or assisted by a myriad of actin-binding proteins in vivo.  
Whether in vivo or in vitro, actin polymerization results in a polarized filament.  Even 
though both ends are capable of adding or subtracting monomers, the plus end (or barbed 
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end), is more likely to add actin monomers than the minus end.  Actin monomers 
hyrdolyze ATP when incorporated into filaments, and actin monomers bound to ATP are 
more likely to polymerize than those bound to GDP, creating this polarization.  
 There exist in the cell a plethora of actin-binding proteins that regulate assembly 
and disassembly of actin filaments; in fact, turnover of actin filaments within the cell is 
100 times faster than it is in vitro (Cooper and Hausman, 2004).  A key complex of 
proteins, the Actin-Related Protein 2/3 (Arp2/3) complex, regulates the initiation of the 
polymerization of new actin filaments (Higgs and Pollard, 2001).  This complex 
functions by binding to existing actin filaments and acting as a nucleation site for a new 
filament (Pollard and Beltzner, 2002).  The discovery of this protein complex unlocked 
the mystery of not only actin polymerization in vivo, but also actin branching.  In addition 
to actin branching, actin filaments are also cross-linked to form a meshwork necessary for 
the stability of the cell cortex and actin-based cell protrusions.  Three actin-based 
structures are linked to cell motility:  lamellipodia, filopodia, and stress fibers. 
 
Lamellae 
 Lamellipodia, or membrane ruffles, have been referred to as the “organelle” of 
motility (Abercrombie et al., 1970).  They are found at the leading edge of migrating cells 
during directed motility, and consist of an intricate network of crosslinked actin 
(Matsudaira, 1994).  Membrane protrusion is based on active actin polymerization; in 
fact, these structures account for the most incorporation of unpolymerized actin in the cell 
(Glacy, 1983).  Also found in lamellipodia are sites of contact between the cell and its 
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substratum (Kaverina et al., 2002).  These contact sites are thought to be important for 
force generation in the migration process (Beningo et al., 2001).  Clearly, lamellipodia 
are important for cell migration, and recent evidence has linked them to malignant 
invasion as well (Condeelis et al., 2001).         
 
Filopodia 
 Filopodia, or membrane spikes, are also tightly linked to cell motility.  Also found 
at the leading edge of migrating cells, filopodia consist of actin filaments aligned in 
parallel bundles (Wood and Martin, 2002).  These actin structures are generally thought 
to function in sensing environmental cues to guide cell migration and lamellipodia 
formation (Wood and Martin, 2002).     
 
Stress Fibers 
 The final actin structure linked to cell motility is the stress fiber.  Stress fibers are 
parallel bundles of actin filaments that provide structure and rigidity to the cell.  An 
overabundance of stress fibers is generally associated with a stationary cellular 
morphology, while the moderate presence of these structures is necessary for motility 
(Vial et al., 2003).  Stress fibers provide a structure necessary for actin-myosin 
contraction and the retraction of the cell body during migration (Katoh et al., 2001).  




Focal Adhesions (FAs) and Focal Adhesion Complexes (FACs) 
Stress fibers and actin filaments end in points of contact between the cell and the 
substratum.  These types of contacts are not only sites that provide structural integrity, 
but they also represent scaffolding sites for cell signaling proteins to congregate and 
function (Wozniak et al., 2004).  The nomenclature is difficult to pinpoint, for there are 
several different types of these structures, each with its own specific protein complement 
found throughout the cell (Geiger et al., 2001).  Essentially, these structures link actin 
filaments with proteins of the extracellular matrix through the transmembrane proteins 
integrins.  Integrins directly contact the extracellular matrix proteins, but require adaptor 
proteins to bind actin (Wozniak et al., 2004).  These adaptor proteins function to provide 
structural support for the cell-matrix junction.   
There can be upwards of 100 proteins in cell-matrix adhesion sites, and many of 
these proteins function as signaling molecules (Geiger et al., 2001).  Signaling molecules 
such as Focal Adhesion Kinase (FAK) and the Rous sarcoma virus gene, Src, are 
recruited to active integrins, and begin a myriad of signaling cascades (Petit and Thiery, 
2000).  FAK initiates cell survival and cell proliferation pathways, as well as those 
associated with cell motility (Mitra et al., 2005).  Src is important for survival signaling, 
as well as cell cycle progression (Parsons and Parsons, 2004).  In fact, if an 
untransformed cell is in suspension or devoid of matrix contacts, it will undergo 





Cell invasion refers to the process by which a cell moves through a three- 
dimensional matrix.  Not only is it necessary for the cell to form actin protrusions, make 
cell-matrix contacts, and retract, but the cell must also clear a path for itself to migrate 
through the maze of interwoven extracellular matrix proteins.  To do this, the cell secretes 
matrix metalloproteinases (MMPs) that digest the proteins of the extracellular matrix.  As 
a group, MMPs have the ability to digest essentially all protein components of the 
extracellular matrix (Kleiner and Stetler-Stevenson, 1999).  Degradation of the basement 
membrane, or the extracellular matrix proteins underlying sheets of epithelia, is essential 
for tumor cell intravasation (Overall and Lopez-Otin, 2002).  Recently, it has become 
evident that the MMP family plays a direct role in tumor progression by regulating the 
tumor microenvironment (Egeblad and Werb, 2002).  Moreover, MMP expression is 
increased in most human cancers compared with normal tissue (Egeblad and Werb, 
2002).  MMP inhibition is currently an active area of study for cancer treatment 
(Folgueras et al., 2004).    
 
1.4 Rho GTPases 
 
 
The Rho GTPases are a family of proteins essential for cell motility.  This family 
consists of 20 proteins, and can be subdivided into five subfamilies that exhibit similar 
properties:  the RhoA-related subfamily, the Rac1-related subfamily, the Cdc42-related 
subfamily, the Rnd subfamily, the RhoBTB subfamily (Burridge and Wennerberg, 2004).  
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Additionally, there are three proteins RhoD, Rif, and TTF/RhoH, which do not fall into 
any of these subfamilies (Wennerberg and Der, 2004).  Very little is known about these 
proteins, and it is questionable whether they are important to cancer progression 
(Burridge and Wennerberg, 2004).  The function and signaling of the RhoBTB proteins is 
completely unknown, and therefore not currently pertinent to metastatic progression 
(Burridge and Wennerberg, 2004).  Rnd subfamily proteins are closely related to the 
RhoA subfamily, but seem to antagonize Rho signaling and lead to cell rounding (Nobes 
et al., 1998).  Again, the role of the Rnd subfamily in the positive regulation of metastatic 
progression is questionable, and therefore not currently relevant. 
 The most intensely studied Rho GTPases are the RhoA-like, Rac1-like, and 
Cdc42-like subfamilies.  There is much evidence that proteins of these subfamilies play 
significant roles in tumor progression to the metastatic state (Benitah et al, 2004, Ridley, 
2004; Sahai and Marshall, 2002).  Members of these families have been shown to be 
overexpressed in human tumors and cancer-associated mutations in Rho protein 
regulators have been characterized (Ridley, 2004).  Furthermore, Rho family proteins 
have been shown to be important for the proper maintenance of epithelial cell-cell 
adhesion (Lozano et al., 2003).  Rho proteins have been implicated not only in motility 





The RhoA-like subfamily consists of RhoA, RhoB, and RhoC.  RhoB regulates 
actin organization and vesicle transport, but has been shown to possess anti-cancer 
function (Prendergast, 2001).  However, RhoA and RhoC are strongly implicated in 
cancer progression (Wheeler and Ridley, 2004).  RhoA has been found to be 
overexpressed in several highly metastatic cancer cell lines and can promote 
transformation of cultured mouse fibroblasts (Ridley, 2004).  Conversely, RhoC cannot 
promote fibroblast transformation, but has been shown to increase in expression levels as 
tumors become increasingly metastatic (Clark et al., 2000; Kleer et al., 2002).  
Additionally, RhoC has been shown to promote metastasis when overexpressed in 
melanoma cells (Clark et al., 2000). 
It is becoming more evident that even though RhoA and RhoC are very closely 
related in cDNA sequence, they function differently in vivo (Wheeler and Ridley, 2004).  
RhoA and RhoC have been shown to activate the formin Diaphanous (mDia), which 
results in actin nucleation that contributes to stress fiber formation (Wallar and Alberts, 
2003).  Additionally, they have also been shown to activate Rho Kinase (ROCK), a 
kinase that elevates Myosin Light Chain (MLC) phosphorylation (Sahai and Marshall, 
2002).  This elevation causes acto-myosin contraction within the cell, which is an 
indispensable step in cell migration (Burridge and Wennerberg, 2004).  Interestingly, 
RhoC appears to exhibit a higher affinity for ROCK and a stronger ability to activate it 
than its isoform, RhoA (Sahai and Marshall, 2002).  This difference could explain the 
different roles played by each isoform in cell motility and cancer progression. 
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Rac1-like and Cdc42-like Subfamilies     
 The Rac1-like subfamily includes three members, Rac1, Rac2, and Rac3.  Rac2 
expression is restricted to hematopoetic cells where is required for function of the 
NADPH oxidase (Dinauer, 2003).  Rac1 and Rac3, exhibiting 92% homology, stimulate 
the formation of lamellipodia and membrane ruffles (Aspenstrom et al., 2004).  Rac1 has 
been strongly implicated in metastatic progression, while a role for Rac3 is beginning to 
become evident (Sahai and Marshall, 2002).   Activating Rac1 causes an increase in 
lamellipod expression and an increase in invasion in transformed, but non-invasive, cells, 
implicating it in tumor progression (Bourguignon et al., 2000).  Additionally, blocking 
Rac1 function curtailed metastasis in an in vivo model (Bouzahzah et al., 2001).  A 
similar role in metastasis for Rac3 has not been shown, even though Rac1 and Rac3 share 
similar downstream effectors (Haeusler et al., 2003). 
 The Cdc42-like subfamily consists of five members, and they all stimulate the 
formation of filopodia (Burridge and Wennerberg, 2004).  However, Cdc42 is the most 
extensively studied protein of the family and has been implicated in cancer progression 
(Schmitz et al., 2000). 
 Rac and Cdc42 share most of the same downstream effectors, due to extensive 
homology of the effector region (Cotteret and Chernoff, 2002).  The major exception to 
this observation is the ability of Cdc42 to bind Wiskott-Aldrich Syndrome Protein 
(WASP) in vivo.  Subsequent to activation by Cdc42, WASP activates Arp2/3, which 
causes actin nucleation and the formation of filopodia (Miki and Takenawa, 2003).  
Ironically, Rac can also activate Arp2/3 in vivo to result in actin polymerization, but 
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through the protein WASP family verprolin homologous (WAVE) (Smith and Li, 2004).  
However, this interaction is not direct:  Rac1 instead directly interacts with either insulin 
receptor substrate 53 (pIRS53), or the protein complex consisting of WAVE1, p-53 
inducible messenger RNA with a relative molecular mass of 125,000 (PIR121), NCK-
associated protein with a relative molecular mass of 140,000 (Nap125), and Heat Shock 
Protein 300 (HSPC300), to activate WAVE (Eden et al., 2002).   
 Downstream effectors shared by Rac and Cdc42 include p-21 activated kinase 
(PAK), PI3-kinase (phosphatidyl inositol 3-kinase), and members of the MAP kinase 
cascades, MEKK1, MEKK4, and Mlks 1,2,3 (Bishop and Hall, 2000).  The most 
intensely studied downstream effector common to both Rac and Cdc42 is PAK.  PAK can 
stimulate cell migration via LIMK, filamin, or its effects on myosin (Bokoch, 2000).  
Additionally, PAK can activate p38MAP kinase and Jun kinase (JNK), which can lead to 
cell proliferation (Bishop and Hall, 2000).  Recent studies have even implicated PAK in 
human cancer (Vadlamudi and Kumar, 2003). 
 
Regulation       
     The Rho GTPases Rho, Rac, and Cdc42 are all active when bound to GTP, and 
inactive when bound to GDP.  When bound to GDP, Rho proteins are sequestered in the 
cytosol by RhoGDI (guanine nucleotide dissociation inhibitor), which masks the prenyl 
group and prevents translocation to the plasma membrane.  Subsequent to RhoGDI 
dissociation, Rho proteins translocate to the plasma membrane where they are activated 
by guanine nucleotide exchange factors (GEFs).  GEFs allow the binding of GTP to the 
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Rho protein by facilitating the dissociation of the GDP.  Rho GTPases have intrinsic 
GTPase ability, but this ability is very weak.  In order to hydrolyze the gamma phosphate 
of the GTP to render the Rho GTPase inactive, a GTPase activating protein (GAP) is 
required.  Clearly, the Rho GTPases are intricately regulated by a myriad of accessory  
proteins. 
                             
Structure, Biochemical Interactions 
The Rho GTPases Rho, Rac, and Cdc42 all contain similar activating and 
structural domains.  The GTPase binding domain is located near the N-terminus.  The 
effector domain, or Switch I region, is located between residues 28-44 in RhoA.  This 
region undergoes a conformational change when GDP is exchanged for a GTP, and this 
conformational change allows the binding of downstream effectors.  Proteins containing 
Cdc42 and Rac interactive binding (CRIB) domains or GTPase binding domains (GBDs) 
bind to the Rho proteins at the Switch I region, which is located close to the N-terminus 
of the protein.  C-terminal to Switch I is the Insert region.  The insert region (residues 
124-135 of Rac1) is the most varied among Rho, Rac, and Cdc42 proteins (Freeman et 
al., 1996).  Even though both downstream effectors and GEFs interact with the Switch I 
domain, the insert region also determines binding affinity of these proteins because 
accessory proteins interact with other domains as well (Schmidt and Hall, 2002).  Finally, 
Rho proteins contain a CAAX box at their n-terminus where these proteins are 
prenylated.  RhoA and RhoC are farnesylated, Rac1 and Cdc42 are geranylgeranylated, 
while Rac3 appears to be both farnesylated and geranylgeranylated (Joyce and Cox, 
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2003).  Overall, slight differences within the structure and amino acid sequence of these 
proteins can account for considerable differences in cellular effects. 
 
Rho Proteins and their Regulators as Potential Cancer Therapeutics 
Because Rho GTPases may act as promoters of metastasis, it has long been 
thought that drugs which specifically alter Rho protein signaling could have significant 
therapeutic value (Martin, 2003).  Because these proteins affect tumorigenesis at various 
levels, including G1-S transition, cell survival, motility and invasion, it follows that 
inhibition of these proteins or downstream effectors could be effective anti-cancer 
therapies.  Recently, a group ahs developed a first generation of compounds that target 
the activity of PAK, a downstream effector of Rac and Cdc42 shown to be necessary for 
Ras-induced transformation (Nheu et al., 2002).  Another area of potential therapy 
currently being explored is the treatment of human tumors that overexpress Rho GTPases 
with non-steroidal anti-inflammatory drugs (NSAIDS) (Benitah et al., 2003).  The 
NSAIDs Sulindac and NS-398 have been shown to decrease proliferation in human tumor 
cells via inhibition of the Rho GTPases (Benitah et al., 2003).  Furthermore, a group of 
anti-hypercholesterolemia drugs known as statins have recently been shown to possess 
anti-tumor effects via the inhibition of the Rho GTPases (Jakobisiak and Golab, 2003).      
The greatest successes with anti-cancer agents that target small GTPases have 
been then farnesyl transferase inhibitors (FTIs).  Tipifarnib (R115777), in particular, has 
enjoyed reasonable success in phase I California Cancer Consortium Trial (Lara et al., 
2005).  The mechanism of activation of FTIs is to inhibit farnesylation of GTPases, 
 19
thereby interfering with translocation to the membrane and effective activation 
(Caponigro, 2002).  Clearly, there is a wealth of possibilities for the development of new 
anticancer drugs that target Rho GTPases.    
 
1.5  PTEN 
 
PTEN (phosphatase and tensin homologue deleted on chromosome ten) is a tumor 
suppressor gene that may also act as a metastasis suppressor.  It encodes a dual-
specificity phosphatase that has been shown to dephosphorylate protein substrates in vitro 
on serine, threonine, and tyrosine residues (Myers et al., 1997).  Additionally, PTEN has 
been shown to dephosphorylate lipids (Maehama and Dixon, 1998).  PTEN has come to 
represent an extremely important protein not just because of its role as a tumor 
suppressor, but also because of its role in embryonic development, cell migration, and 
apoptosis (Yamada and Araki, 2001).  PTEN has emerged as a significant modulator of 
cell signaling, growth, migration, as well as apoptosis.   
 
PTEN as a Tumor Suppressor 
By the mid-1990’s, genetic evidence strongly suggested a tumor suppressor was 
located on chromosome 10 of the human genome (Parsons and Simpson, 2004).  One 
alteration that was found to occur at high frequency in a variety of human tumors was the 
loss of heterozygosity at chromosome 10q23 (Tamura et al., 1999).  Therefore, the search 
began for a novel tumor suppressor gene from that region.  In 1997, three independent 
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research labs cloned a tumor suppressor gene from region 10q23, and was referred to as 
PTEN, MMAC1 (mutated in multiple advanced cancers) or TEP1 (transforming growth 
factor beta-regulated and epithelia cell-enriched phosphatase) (Waite and Eng, 2002).  
Not only is PTEN found to be deleted or mutated in many types of somatic cancers, but 
germline mutations in the gene have been found in individuals with Cowden Syndrome 
(Waite and Eng, 2002).  Cowden Syndrome is an autosomal dominant disorder that is 
characterized by multiple hamartomas that affect derivatives of all three germ layers and 
by a risk of breast, thyroid, and endometrial neoplasias (Eng, 2000).  Notably, this 
finding represented the first phosphatase gene that had been implicated in the etiology of 
an inherited cancer syndrome (Waite and Eng, 2002).  Undoubtedly, PTEN is a 
fascinating protein with great clinical, as well as historical, significance.   
 
Structure, Biochemical Interactions 
The crystal structure of PTEN was solved in 1999, which shed insights into its 
phosphatase activity and membrane association (Lee et al., 1999).  Essentially, the PTEN 
structure consists of the N-terminal phosphatase domain (179 residues) and the C-
terminal C2 domain (166 residues) (Lee et al., 1999).  The phosphatase domain contains 
the active site pocket, which contains a P loop that is similar to those found in other 
protein tyrosine phosphatases (PTPs) (Lee et al., 1999).  Unlike these other phosphatases, 
however, this pocket contains an extension that widens the pocket and allows the binding 
of the larger lipid substrates (Lee et al., 1999).  The C2 domain contains structures 
consistent with membrane association, and indeed does associate with phospholipid 
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membranes in vivo (Das et al., 2003).  This membrane localization is thought to be 
important for activation of the protein and to enable the protein to interact with its 
membrane-bound substrates (Das et al., 2003). 
 
Signaling and Regulation 
PTEN, as mentioned earlier, can dephosphorylate tyrosine, serine, and threonine 
residues, as well as phosphorylated lipids.  In vitro, PTEN has been shown to 
dephosphorylate FAK and Shc (Src and collagen homologue), which are proteins known 
to be important in motility and survival (Gu et al., 1999).  However, the relative 
importance of this enzymatic function in vivo compared to its lipid phosphatase activity 
has been controversial (Yamada and Araki, 2001).  Moreover, most research has focused 
on PTEN’s ability to dephosphorylate lipids, in particular phosphatidyl inositol (3,4,5)-
phosphate (PIP3), so this is where most of the information lies (Goberdhan and Wilson, 
2003). 
 The primary biological function of PTEN is to antagonize phosphatidyl inositol 3-
kinase (PI3-kinase) signaling, by converting PIP3 back to the PI3-kinase substrate PIP2 
(Goberdhan and Wilson, 2003).  Even though PIP3 acts a second messenger and has 
many substrates within the cell, PTEN expression has been found to mostly affect cellular 
processes regulated by the PIP3 downstream effector Akt (or PKB-protein kinase B) 
(Leslie and Downes, 2002).  Akt has been shown to be a negative regulator of molecules 
that inhibit cell proliferation and survival (Leslie and Downes, 2002).  However, the lack 
of PTEN has been shown to increase motility via Rac and Cdc42 (Liliental et al., 2000).  
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Clearly, PTEN is capable of regulating processes in primary tumorigenesis, as well as in 
invasion and metastasis.    
 PTEN activity is regulated by phosphorylation, localization, and transcription.  
When phosphorylated on serine and threonine residues in the C-terminal tail, PTEN is 
most likely monomeric and cytosolic (Leslie and Downes, 2004).  The function of 
phosphorylation is controversial, but it appears to stabilize and reduce the activity of the 
protein (Leslie and Downes, 2002).  In most cell types, PTEN appears to be largely 
cytosolic, thus requiring membrane localization to act on its downstream target PIP3 
(Leslie and Downes, 2002).   The C2 domain possesses intrinsic and significant 
membrane-binding potential, and this potential appears to be specific for acidic, 
phosphotidyl-inositol containing membranes (Maehama et al., 2004) (Leslie and Downes, 
2004).   The MAGI (membrane associated guanylate kinase with inverted orientation) 
proteins are also known to physically interact with PTEN via their PDZ domain, thereby 
resulting in an additional way that PTEN can be targeted to the membrane (Leslie and 





The major cause of death from cancer is metastasis to the vital organs.  Although 
it may be possible to eradicate a primary tumor by surgery or other therapeutic 
intervention, there is no effective therapy for advanced metastatic cancer.  For breast 
cancer, the transition form a primary tumor to invasive cancer is estimated to average six 
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years, which provides ample time for therapeutic intervention (ACS 2005).  
Unfortunately, the mechanisms that underlie the malignant progression of this cancer are 
not very well understood, and there are very few proteins that have been identified as 
regulators of metastasis.  Thus, understanding the progression of breast cancer to the 
metastatic state and the molecular changes that take place in malignant primary breast 























PTEN (phosphatase and tensin homologue deleted on chromosome ten) is a tumor 
suppressor gene that has been shown to be essential for normal cell development, but 
deleted or mutated during tumorigenesis in certain cancers and cancer predisposition 
syndromes (Bonneau and Longy, 2000; Dahia, 2000; Ali et al., 1999).  Experimental 
mutational analysis of PTEN has been shown to result in unbalanced cell proliferation 
and cell survival (Vazquez and Sellers, 2000).  In addition, it has been thought that the 
chromosome region where PTEN is located, region 10q22-24, includes one or more 
genes that play a role in several human malignancies (Dahia, 2000).  PTEN deletions and 
mutations can occur during early stage transformation, or can be correlated with 
advanced cancer grade (Goberdhan and Wilson, 2003).  With respect to endometrial and 
ovarian cancers, PTEN mutation tends to be found in the earlier stages (Vazquez and 
Sellers, 2000).  Conversely, PTEN mutation is found to increase with respect to an 
increase in malignancy or higher grade tumors in glioblastoma and prostate tumors 
(Vazquez and Sellers, 2000).   However, the degree to which PTEN can be used as a 
predictor of outcome is not known, and requires further study (Vazquez and Sellers, 
2000).    
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Substrates of PTEN 
PTEN is thought of as a dual specificity phosphatase, as it can dephosphorylate 
both protein and lipid substrates.  One protein substrate shown to interact with PTEN is 
focal adhesion kinase (FAK).  FAK is a key regulatory molecule in the processes of 
growth factor and integrin-stimulated cell motility and proliferation.  In transformed cells 
and in analysis of human tumors, elevated FAK expression and activity have been 
correlated with progression to a malignant phenotype (Schlaepfer and Mitra, 2004).  
Studies have shown that PTEN interacts with FAK in vitro and causes dephosphorylation 
of its tyrosine residues (Gu et al., 1998; Tamura et al., 1998).  Initially, PTEN regulation 
of FAK was an exciting and promising prospect in the investigation of cancer metastases, 
but this work has been irreproducible, and may be cell-line specific (Waite and Eng, 
2002). 
 A more plausible substrate for PTEN is the lipid phosphoinositide (3,4,5)-
trisphosphate (PIP3) (Dahia, 2000; Kandel and Hay, 1999; Stambolic et al., 1999; 
Tamura et al., 1999; Besson et al., 1999).   The enzyme phosphoinositide 3-kinase (PI3-
kinase) phosphorylates PIP(3,4)2 to yield PIP(3,4,5)3, thereby classifying PTEN as a 
PI3-kinase antagonist.  PIP3 is a quantitatively minor phosphoinositide, rapidly and 
transiently produced in response to agonist stimulation.  However, PIP3 acts as a critical 
second messenger molecule able to control the spatiotemporal organization of signaling 
pathways at the plasma membrane (Payrastre et al., 2001).  Pathways regulated by PIP3 
include cell survival and proliferation, cell motility and organization of the cytoskeleton, 
as well as glucose metabolism (Rameh and Cantley, 1999).  Cells that lack PTEN are 
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unable to regulate the processes controlled by PIP3, which stimulates a variety of cellular 
phenotypes that favor oncogenesis and malignant progression (Sulis and Parsons, 2003).  
 
PTEN in Motility and Invasion 
 PTEN has recently been implicated in the processes of motility and chemotaxis.  
Expressing ectopic PTEN in PTEN null cells inhibits cell migration (Tamura et al., 
1998).  Moreover, PTEN-null fibroblasts show enhanced rates of migration, which can be 
reduced by re-introduction of PTEN (Liliental et al., 2000).  Originally, because PTEN 
had been shown to dephosphorylate FAK (focal adhesion kinase) in vitro, it was thought 
that this was the mechanism behind the regulation of cell motility by PTEN (Tamura et 
al., 1999).  However, more research has shown that PTEN regulates motility by 
downregulation of the small GTPases Rac and Cdc42, via inactivation of PIP3 (Stiles et 
al., 2004; Liliental et al., 2000).  Data from Dictyostelium has recently shown that 
localization and translocation of PTEN following a chemotractant stimulation is 
reciprocal to PI3-kinase location (Iijima et al., 2002) (Iijima and Devreotes, 2002).  This 
model suggests that a chemotractant causes PI3-kinase to localize to the leading edge of 
the membrane, leading to PIP3 accumulation, Akt activation, and the formation of a 
pseudopod via PI3-kinase induced Rac activity.  In parallel, PTEN dissociates from the 
leading edge of the membrane and relocates posteriorly, thus allowing more PIP3 to 




PTEN in Human Breast Cancer  
In contrast to some cancers, only about 6-10% of breast cancers tested to date 
have inactivated PTEN (Li et al., 1997) (Cantley and Neel, 1999).  In breast cancers, 
PTEN deletions do not play a dominant role in primary tumorigenesis according to PTEN 
mutational analysis of primary breast cancers (Perren et al., 1999).  However, PTEN 
dysfunction may play a role in advanced breast cancer, as was shown in more invasive 
breast carcinomas (Bose et al., 2002).  The loss of PTEN has been shown to predict 
resistance to chemotherapeutic treatment in breast cancer (Pandolfi, 2004).  Moreover, 
reduced PTEN expression has been associated with poor outcome and angiogenesis in 
invasive ductal carcinoma of the breast (Lee et al., 2004).  Additionally, reduced PTEN 
expression predicts relapse in patients with breast carcinoma treated by tamoxifen 
(Shoman et al., 2005).  Clearly, there is a link between PTEN expression and advanced 
breast cancers.  Exploration into the mechanisms by which PTEN affects breast cancer is 
crucial to understanding and preventing further mortality.  Therefore, the role of PTEN in 
malignant breast cancer requires further investigation.  
We hypothesize that due to its decreasing expression in invasive breast cancer 
tissue and its central role in regulating cellular motility, PTEN is a negative regulator of 
metastasis in human breast cancer.  To test this hypothesis, we investigated endogenous 
PTEN and PI3-kinase expression in a range of human breast cancer cells.  We localized 
PTEN both prior and subsequent to stimulation, and colocalized the protein with 
proposed downstream effectors involved in motility signaling pathways.  Finally, we 
show that exogenous PTEN expression negatively modulates cell motility in invasive, 
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metastatic human breast cancer cells.  Taken together, these data represent an 
investigation into the role of PTEN and its downstream effectors in the invasive 
capabilities of human breast cancer.  
 
2.2 Materials and Methods 
 
Cell Culture 
Metastatic human breast cancer cell lines T47D, HS578t, MDA-MB-231 and 
MDA-MB-435 were cultured in supplemented minimum essential medium (GibcoTM, 
CA) with 10% fetal bovine serum (Tissue Culture Biologicals, CA) and incubated in a 
humidified 5% CO2 atmosphere at 37°C.  
 
Immunoblotting 
Proteins from total cell lysate were separated by 10% SDS-PAGE gel, transferred 
to a nitrocellulose membrane, and probed with a mouse monoclonal anti-PTEN antibody 
(Cell Signaling, MA) or a rabbit polyclonal anti-PI3 kinase p85 subunit alpha antibody 
(Santa Cruz, CA).  Immunoblots were detected subsequent to incubation with an HRP-
conjugated secondary antibody (Pierce Endogen, IL) with the SuperSignal West Femto-
Substrate chemiluminescence kit (Pierce Endogen, IL) and Kodak Biomax MR film 
(Fisher Scientific, TX).  
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Stimulation and Immunostaining of Breast Cancer Cells 
Cells were cultured on coverslips, and starved for 24 to 48 hours prior to 
stimulation with Heregulin (Neomarkers, CA).  Cells were fixed subsequent to 
stimulation with 4% paraformaldehyde (Sigma Chemical Corp., MO), permeabilized with 
0.5% Triton X-100 (Sigma, MO), and blocked with 5% goat serum (GibcoTM, CA)  and 
5% BSA (Sigma Chemical Corp., MO) in 1XPBS.  To visualize localized PTEN, cells 
were incubated with anti-PTEN antibody (Cell Signaling, MA) followed by a secondary 
antibody conjugated to FITC (Pierce, IL).  Cells were imaged using an Olympus upright 
fluorescence microscope, and digital pictures were taken with Spot Advanced digital 
camera software (Diagnostic Instruments Inc., MI).  
 
Exogenous PTEN Expression and PIP3 staining 
 GFPPTEN vector (kind gift of Kenneth Yamada, NIH) was transfected into the 
MDA-MB-231 cell line using Lipofectamine Plus Reagent (GibcoTM, CA).  Maximal 
expression was achieved 24-48 hours post transfection.  PTEN was introduced into 
MDA-MB-435 cell line via the Rev Tet-Off stable gene expression system (Clontech, 
CA).  Briefly, cells were retrovirally transfected with the plasmid encoding the Tet-Off 
regulatory protein and selected until stable.  Cells were then retrovirally transfected with 
the plasmid containing the gene of interest fused to the Tet response element.  Cells 
expressing both plasmids were then selected by drug selection (puromycin resistance). 
Gene induction was achieved by removing the repressing antibiotic, doxycycline.   
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Subsequent to PTEN expression, cells were fixed and stained with a mouse 
monoclonal antibody to PIP3 (Echelon, UT) followed by an IgM secondary antibody 
conjugated to FITC (Pierce, IL).   
 
Rac Activity Assay    
 Rac activity assays were performed as described in (Benard et al., 1999) with 
minor modifications.  Briefly, cells were washed twice with 1X PBS, lysed with 1X ice 
cold lysis buffer, and scraped from the plate.  Lysates were then incubated at 4° for 1 
hour with 10µg of PAK-PBD Protein GST Beads (Cytoskeleton Inc., CO).  The bead 
pellet was then washed once with wash buffer containing 1% Nonidet P-40 (Calbiochem, 
CA) and twice without Nonidet P-40.  The bead pellet was finally suspended in 20 µl 
Laemelli sample buffer.  Proteins from total cell lysate, as well as the bead pellet, were 
separated by 10% SDS-PAGE gel, transferred to a nitrocellulose membrane, and blotted 
using a monoclonal anti-Rac (clone 32A8) antibody (Upstate Biotechnology, NY).  
Immunoblots were detected with the SuperSignal West Femto-Substrate 
chemiluminescence kit (Pierce Endogen, IL) and Kodak Biomax MR film (Fisher 
Scientific, TX).  
 
Wound Healing Assay 
Cells were cultured on coverslips until 100% confluency, then transfected with 
GFPPTEN vector.  36 hours post transfection, cells were again confluent and were 
stimulated by wounding as described in (Nobes and Hall, 1999).  Wound healing assays 
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were performed by wounding a confluent monolayer of cells with a sterile 21G11/2 
Precision GlideTM needle (Becton Dickinson and Co., NJ).  Cells were fixed with 4% 
formaldehyde (Sigma Chemical Corp., MO) six hours subsequent to wounding.  To 
visualize actin cytoskeleton, cells were stained with rhodamine phalloidin (Molecular 
Probes Inc., OR).  Cells were imaged using an Olympus upright fluorescence microscope, 
then photographed with Spot Advanced digital camera software (Diagnostic Instruments 
Inc., MI).  
 
Apoptosis Assay 
Cells were plated on coverslips, transiently transfected with GFPPTEN and 
assayed for cell death 24, 36, and 48 hours post transfection.  Briefly, cells were fixed 
and permeablized in ice-cold 70% ethanol and incubated with RNase A (Sigma, MO) and 
propidium iodide (Sigma, MO) at 37 degrees for 30 minutes.  Under the Olympus upright 
fluorescent scope, the areas of control cell nuclei (Lipofectamine alone) as well as those 
cells expressing GFPPTEN, were traced and calculated using Spot Advanced digital 
camera software (Diagnostic Instruments Inc., MI).      
      
2.3 Results 
 
PTEN expression decreases as metastatic efficiency increases in human breast 
cancer cells.   
 Although similar data was subsequently published by others, 
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(Chung et al., 2004; Bose et al., 2002), a direct correlation was found between breast 
cancer progression and PTEN expression (Figure 2.1).  The T47D breast cancer cell line 
is derived from a primary human breast tumor, is not invasive in in vitro studies, and 
expresses a relatively high amount of endogenous PTEN.  The HS578T and MDA-MB-
231 breast cancer cell lines are low metastatic, invasive, and express some endogenous 
PTEN.  The MDA-MB-435 cell line is a highly metastatic, highly invasive cell line that 
expresses almost no endogenous PTEN.  Because of this result, we were encouraged to 
investigate PTEN as a regulator of metastasis, and not primary tumorigenesis, in human 
breast cancer. 
Additionally, the expression of PI3-kinase was found to be directly correlated 
with breast cancer progression:  PI3-kinase expression decreased with decreased 
metastatic progression (Figure 2. 1).  Recent studies have suggested that PTEN and PI3-
kinase exhibit a reciprocal relationship with respect to motility in Dictyostelium 
(Funamoto et al., 2002).  Our data shows that those cells exhibiting the more invasive 
phenotype have lower levels of endogenous PTEN and higher levels of PI3-kinase, and 
those exhibiting the less invasive phenotype have higher levels of PTEN and lower levels 
of PI3-kinase.  This observation supports the idea that PTEN and PI3-kinase exhibit a 
reciprocal relationship in regulation in human breast cancer:  PTEN acts as a PI3-kinase 





PTEN translocates away from the leading edge the cell upon stimulation. 
To understand the role of PTEN in breast cancer cells following PI3-kinase 
activation, we investigated the subcellular localization of PTEN following heregulin 
stimulation in MDA-MB-231 breast cancer cells.  In the low metastatic cell line MDA-
MB-231, endogenous PTEN localizes to the leading edge of quiescent cells (Figure 2.2).  
However, upon stimulation with the growth factor heregulin, which stimulates 
EbrB2/Her2 receptors to stimulate PI3-kinase, PTEN appears to move away from the 
leading edge of the cell.  Because of this result, we hypothesized that PTEN was acting as 
a negative regulator of PIP3 at the membrane of the leading edge in resting cells. At rest, 
PTEN is localized uniformly at the membrane, inactivating PIP3 subsequent motility 
signals.  Upon stimulation, PTEN retreats from the leading edge, allowing PI3-kinase to 
activate PIP3 and classical chemotactic responses.  This is currently the working model 
for PI3-kinase/PTEN mediated chemotaxis (Funamoto et al., 2002). 
 
PTEN localizes with focal adhesions in breast cancer cells under normal serum 
conditions. 
 Focal adhesions are sites of cell-matrix adhesion and are essential to 
understanding the process of cell motility.  They represent highly regulated signaling 
scaffolds, which signal for motility, survival, as well as proliferation (Carragher and 
Frame, 2004).  Many key proteins involved in migratory pathways have been localized to 
focal adhesions, including FAK and PI3-kinase (Brunton et al., 2004).  Our data localizes 
PTEN to the same cellular regions in which focal adhesions are found in metastatic 
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human breast cancer cells while under normal tissue culture conditions in serum (Figure 
2.3).  This observation again implicates PTEN in the regulation of motility and invasion 
in human breast cancer.   
 
PTEN colocalizes with FAK in breast cancer cells under normal serum conditions. 
 Not only does our data place PTEN at focal adhesions, but we can also colocalize 
PTEN with FAK (Figure 2.4).  FAK is a versatile protein known to participate in a 
myriad of signaling cascades (Mitra et al., 2005).  Not only can FAK activate the small 
GTPases Rac and Cdc42 to result in active motility, but activated FAK can also protect 
the cell from apoptosis and activate MAP kinase signaling (Schaller, 2001).  PTEN has 
been shown to have the ability to dephosphorylate, and subsequently deactivate, FAK in 
vitro (Tamura et al., 1999).  Deactivation of FAK could have severe consequences in the 
cell, including inhibition of motility, as well as programmed cell death (Schaller, 2001).  
Because we can place PTEN in very close proximity to FAK, and FAK has been shown 
to be a substrate of PTEN, we propose that PTEN is directly dephosphorylating FAK in 
vivo, in human breast cancer cells.                                                     
 
Ectopic PTEN expression reduces PIP3 expression in MDA-MB-231 and MDA-MB-
435 breast cancer cell lines. 
PIP3 has been shown to be a substrate of PTEN both in vitro and in vivo (Sulis 
and Parsons, 2003).  PTEN dephosphorylates PIP3 at the D3 position of the inositol ring, 
effectively antagonizing PI3-kinase activity.  We show a reduction in PIP3 levels in both 
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an invasive, highly metastatic cell line (MDA-MB-435) with low endogenous PTEN 
expression, and an invasive, low metastatic (MDA-MB-231) cell line with endogenous 
PTEN expression subsequent to the ectopic expression of PTEN (Figures 2.5 and 2.6).  
Figure 2.5 demonstrates the decrease in PIP3 in response to PTEN expression in MDA-
MB-231 breast cancer cells.  Those cells expressing GFP-tagged PTEN exhibit a marked 
difference in their PIP3 expression levels compared to the non-transfected controls.  
Because PTEN is a tumor suppressor, and negatively regulates pathways of survival and 
proliferation, ectopic PTEN expression has been found to cause apoptosis is several types 
of cells (Parsons and Simpson, 2003).  However, apoptosis is not occurring up to 48 
hours post transfection in MDA-MB-231 cells, therefore, the downregulation of PIP3 
observed in our studies is not due to cellular apoptosis (Figure 2.6).  Figure 2.7 
demonstrates a decrease in PIP3 expression in response to ectopic PTEN expression in 
MDA-MB-435 breast cancer cells, without significant apoptosis (Figure 2.8).    
Additionally, it has been previously reported that ectopic PTEN expression results in a 
downregulation of Rac in fibroblasts (Liliental et al., 2000).  However, no such 
downregulation was found in MDA-MB-435 cells (Figure 2.9).   
Furthermore, the endogenous PIP3 expressed in MDA-MB-231 appears to be 
lesser of that expressed in MDA-MB-435 (Figure 2.5, right panel, Figure 2.7b, left 
panel).  This effect is presumably due to the endogenous PTEN levels exhibited in these 
cells.  Evidence to support this conclusion is present in Figure 2.1.  Figure 2.1 shows 
endogenous PI3-kinase expression as well as endogenous PTEN.  MDA-MB-231 appears 
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to exhibit higher levels of PI3K than MDA-MB-435.  Therefore, higher levels of PIP3 
found in MDA-MB-435 could not be a result of elevated PI3-kinase levels. 
 
Ectopic PTEN expression negatively regulates migration in metastatic human breast 
cancer cells without causing apoptosis. 
 Subsequent to stimulation in a wound healing assay, cells expressing ectopic 
PTEN fail to polarize and migrate as compared to control cells (Figure 2.10).  Control 
cells exhibit a motile and polarized phenotype as demonstrated with actin staining (left 
panels), migrating toward the stimulus.  Cells not expressing ectopic PTEN form 
lamellipodia towards the stimulus, a process which is a hallmark of both motility and 
invasion.  Conversely, those cells expressing the GFP-tagged PTEN construct (right 
panels) exhibit no polarization or motility toward the stimulus.  These cells form no 
lamellipodia towards the wound edge, which is indicative of a stationary cell.  GFPPTEN 
expression does not cause apoptosis in cells up to 48 hours post transfection, so the 




PTEN is a tumor suppressor in several types of cancer, including prostate cancer , 
endometrial cancer, and glioblastoma.  However, PTEN is missing in only 11% of in situ 
breast cancers, compared to 38% of invasive cancers (Bose et al., 2002).  Data presented 
here show that decreasing PTEN expression directly correlates with increasing invasive 
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and metastatic potential of breast cancer cell lines.  Therefore, we formulated the working 
hypothesis is that PTEN acts as a negative regulator of metastatic progression in human 
breast cancer.  The eventual aim of this research was to test the innovative concept of 
PTEN acting as a metastasis suppressor in breast cancer. 
 
PTEN and the PI3-kinase Product, PIP3 
First, we demonstrated that PTEN retreats from the leading edge of the cell upon 
stimulation with growth factor (heregulin).  We hypothesized that this was a reciprocal 
relationship with PI3-kinase, allowing PI3-kinase to phosphorylate PIP2 to yield PIP3 
upon stimulation.  This is now the current model for the regulation of cellular motility 
during chemotactic responses (Funamoto et al., 2002).  Presumably, endogenous PTEN 
negatively regulates motility by being active at the leading edge.  At the leading edge, 
PTEN downregulates the amount of PIP3, which signals to the Rho GTPases to induce 
cellular motility.  Subsequent to stimulation, PTEN moves away from the leading edge, 
allowing PIP3 to accumulate and activate downstream signals (Funamoto et al., 2002).      
Additionally, ectopic PTEN expression was shown to reduce endogenous PIP3 
levels in two different human metastatic breast cancer cell lines without causing the cells 
to undergo apoptosis.  Ideally, cells with less endogenous PTEN exhibit enhanced 
migratory abilities due to the upregulation of PIP3 and subsequent Rho GTPase 
activation (Liliental et al., 2000).  To support this, we show that ectopic PTEN reduces 
the ability of the MDA-MB-231 cell line to react effectively to stimulus.  Therefore, the 
model becomes obvious:  PTEN downregulates PIP3, which negatively regulates motility 
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pathways.  However, ectopic PTEN expression has no effect on Rac activation in MDA-
MB-435 cells.  Classically, it has been assumed that PIP3 activates motility via the small 
GTPases due to the ability of PIP3 to activate guanine nucleotide exchange factors 
(GEFs) that are known to activate Rho, Rac, and Cdc42 (Rameh and Cantley, 1999).  
Perhaps other motility pathways are being downregulated instead.  Akt, or PKB, is itself 
an oncogene that acts downstream of PIP3 to activate cell survival (Toker, 2000). 
Recently, Akt has been shown to activate motility pathways, as well as cell survival 
pathways, in U87MG human glioma cells (Kim et al., 2005; Pu et al., 2004).  
Furthermore, Akt activation has been correlated with tumor invasion and oncogene 
expression in thyroid cancer (Vasko et al., 2004).  Another downstream effector of PIP3 
is PKC (protein kinase C) (Rameh and Cantley, 1999).  Classically, PKC activation by 
PIP3 was thought to activate cell proliferation (Rameh and Cantley, 1999).  However, 
recent evidence has shown that PKC could be involved in cell motility via the production 
of certain metalloproteinases (Urtreger et al., 2005).  Clearly, Rac is not the only protein 
activated by PIP3 that could increase cell motility.   
 
PTEN and its Protein Substrate, FAK 
Additionally, PTEN was shown to localize to focal adhesion and colocalize with 
FAK in human breast cancer cells.  Focal adhesions are multimolecular complexes of 
signaling scaffolds and structural proteins, and it is possible that PTEN could be acting at 
these sites.  FAK, a protein often used as a marker for focal adhesion sites, has been 
shown to be a substrate of PTEN (Tamura et al., 1999).  It would be easy to explain the 
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effect PTEN has on motility by assuming that PTEN does directly deactivate FAK, and 
we present good evidence to support this model.  Furthermore, researchers have reported 
a clear PTEN/FAK relationship in their model systems (Zhang et al., 2003; Zhang et al., 
2004; Gautam et al., 2003).  However, the experiments in which FAK was found to be a 
direct substrate of PTEN are somewhat controversial, and have been unable to be 
repeated by other groups (Yamada and Araki, 2001).  Because of this, most research has 
focused on the lipid-phosphatase activity of PTEN in contrast to its protein phosphatase 
activity.    
It is possible that colocalization does not necessarily mean that PTEN is directly 
dephosphorylating FAK.  PTEN is admittedly found at the leading edge of migrating 
cells, and so is FAK, when present in focal adhesions (Webb et al., 2004).  PI3-kinase is 
also found at the leading edge in migrating cells (Chung and Firtel, 2002).  It is possible 
that PTEN is directly dephosphorylating PIP3, which is initiating a cascade of signals that 
result in the negative regulation of motility.  A negative regulation of motility is most 
likely going to affect FAK, whether direct or indirectly, because of the central role FAK 
plays in regulating motility.  Clearly, more experiments are needed to show a direct 
dephosphorylation of FAK by PTEN in human breast cancer.    
 
Conclusion 
 In conclusion, the data presented here would be much stronger with additional 
experiments.  More precisely, the data would be much stronger with a stable cell line.  
Because PTEN has been shown to cause apoptosis in cells, and the nude mouse model of 
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experimental metastasis was proposed to show the efficacy of PTEN as a bona fide 
metastasis suppressor, the Tet-Off repressor system was used to make the stable cell lines 
expressing ectopic PTEN.  Efforts to produce this stable line with Clontech’s Tet-Off 
Repressor System were unsuccessful, but not without a brief period of success (refer to 
figure 2.7).  Taken together, promising preliminary data was achieved, but the project 

















































Figure 2.1.  Expression of PI3-kinase and PTEN in breast cancer cell  lines.  Whole 
cell lysates of the non-metastatic breast cancer cell lines T47D and Hs578T and the 
metastatic breast cancer cell lines MB-231 and MB-435 were subjected to SDS-PAGE 
followed by western blotting for PI3-kinase using an anti-p85 antibody (top panel) and 
PTEN using an anti-PTEN antibody (bottom panel).  Equal loading of lanes was 
































Figure 2.2.  PTEN distribution in response to stimulation.  MDA-MB-231 cells were 
plated on coverslips, and either serum  starved (upper panel) or starved and then 
stimulated for  15 minutes with heregulin (lower panel).  Cells were then fixed and 
subjected to immunocytochemistry with an antibody to PTEN followed by a secondary 










Figure 2.3.  Subcellular localization of PTEN and focal adhesions.  MDA-MB-231 
cells were plated on coverslips and immunostained for focal adhesions with a monoclonal 
anti-phosphotyrosine antibody and PTEN with a polyclonal anti-PTEN antibody.  Anti-
phosphotyrosine incubation was followed by a mouse secondary antibody conjugated to 
FITC; anti-PTEN incubation was followed by a rabbit secondary antibody conjugated to 






Colocalization of FAK and PTEN in 231
 
Figure 2.4.  Localization of FAK and PTEN in MDA-MB-231 breast cancer cells.  
Cells were plated on coverslips, fixed, and immunostained for FAK and PTEN.  To 
localize FAK, a mouse monoclonal anti-FAK antibody was used, followed by an anti- 
mouse secondary antibody conjugated to FITC.  To localize PTEN, a rabbit polyclonal 
anti-PTEN antibody was used, followed by an anti-rabbit secondary antibody conjugated 
to rhodamine.  Rows represent the same microscopic fields, columns represent different 
fluorescent fields.  The right-most column represents an overlay using Adobe Photoshop 



























Figure 2.5.  Ectopic PTEN expression and endogenous PIP3 expression.  MDA-MB-
231 cells were transiently transfected with GFP-tagged PTEN construct.  Cells were then 
fixed and stained with an antibody to PIP3, followed by rhodamine conjugated secondary 
antibody.  Upper and lower rows represent the same microscopic field, left column is 
DIC, middle column is GFP (PTEN) visualized with an FITC filter, right most panel is 









Figure 2.6.  Viability of MDA-MB-231 breast cancer cells subsequent to ectopic 
PTEN expression.  Apoptosis assays were performed by staining the nuclei of MDA-
MB-231 cells with propidium iodide 24, 36, and 48 hours post-transfection with 
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Figure 2.7.  Endogenous PIP3 levels and ectopic PTEN expression.  MDA-MB-435 
cells were stably transfected with the Tet-Off repressor system from Clontech, expressing 
either control vector or PTEN.  24 hours post removal of doxycycline, PTEN expression 
was determined by western blot with an anti-PTEN antibody (a) and PIP3 expression was 
determined by immunofluorescence using an anti-PIP3 antibody followed by a secondary 









Figure 2.8.  Viability of MDA-MB-435 cells subsequent to ectopic PTEN expression.  
Apoptosis assays were performed by staining the nuclei of MDA-MB-435 cells with 







































Figure 2.9.  Rac activity levels subsequent to ectopic PTEN expression.  Whole cell 
lysates of MDA-MB-435 cells ectopically expressing GFPPTEN were subjected to 
immunoblot for GFPPTEN, endogenous PTEN, and endogenous Rac expression.  Cells 
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Fig 2.10.  Ectopic PTEN expression curtails migration.  GFPPTEN (kind gift of 
Kenneth Yamada of the NIH) was transfected into a confluent monolayer of MDA-MB-
231 cells.  36 hours post-transfection cells were wounded, allowed to migrate, fixed and 
stained with rhodamine phalloidin.  Left column, cells stained with rhodamine phalloidin.  
Right column, same cells visualized with FITC filter to visualize GFP-fluorescence.  
White lettering in the left panels represents the area where the wound was made (wound 
edge). 
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To undergo metastatic transformation, cells must sense signals that inform them 
to actively migrate through the three-dimensional network of the proteins of the 
extracellular matrix (ECM).  When epithelial cells, such as mammary cells, undergo 
metastatic transformation, they must migrate through the basement membrane, which is a 
type of ECM that is organized in to thin, specialized sheets.  Hallmarks of this process 
include invasive morphology, migratory phenotype, and hyperactivation or 
overexpression of the proteins that regulate these processes.  Such proteins include the 
integrin family of transmembrane receptors as well as the Rho family of small GTPases, 
Rho, Rac, and Cdc42.    
 
Integrins in Metastasis 
Integrins are heteromeric, transmembrane glycoproteins that serve as the interface 
between the actin cytoskeleton and the proteins of the extracellular matrix (ECM).  These 
heterodimers contain an α and a β subunit, both of which make important contributions to 
various aspects of overall integrin function.  Upon activation, the integrin heterodimers 
cluster into specialized adhesive structures, focal adhesions (FAs) and focal contacts 
(FACs), in which numerous structural and signaling components are concentrated 
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(Schoenwaelder and Burridge, 1999; Hynes, 2002; Martin et al., 2002).  During 
metastatic progression, cancer cells undergo constant interaction with their immediate 
environment via these focal adhesion contacts, resulting in a myriad of integrin-mediated 
signaling cascades (Mercurio et al., 2001; Petit and Thiery, 2000; Petit and Thiery, 2000).  
Aberrant integrin expression, and the subsequent disregulation of FACs, has been 
implicated in the progression of tumor invasion and the process of metastasis 
(Brakebusch et al., 2002; Kassis et al., 2001).  Specifically, higher expression of α6 
integrin was associated with the metastatic phenotype and malignant progression of 
breast cancer cells (Mukhopadhyay et al., 1999; Shimizu et al., 2002).  In addition, high 
expression level of α6 in human breast carcinoma has been correlated with tumor 
progression and poor prognosis (Friedrichs et al., 1995; Tagliabue et al., 1998). 
 
α6β1 Integrin in Metastatic Progression 
The α6 integrin dimerizes with either β4 or β1 to bind laminin, the major 
constituent of the basement membrane (Hintermann and Quaranta, 2004).  Because 
MDA-MB-435 cells do not express the β4 integrin, motility in this cell line is mainly 
associated with α6β1 integrin (Wewer et al., 1997; Mukhopadhyay et al., 1999).  Many 
studies have demonstrated a critical role for the β1 integrin in cell migration, invasion, 
and supramolecular assembly of extracellular matrix proteins (Brakebusch et al., 1997; 
Sakai et al., 1998).  Studies have shown that cells lacking the beta1 integrin subunit have 
poor directed cell migration to platelet-derived growth factor or epidermal growth factor, 
ligands of receptor tyrosine kinases (Sakai et al., 1998).  Additionally, β1 integrin has 
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shown to be overexpressed in certain invasive cancers, and is required for the invasive 
behavior of these cells (Brockbank et al., 2005).  To explain this link between integrin β1 
and invasion, studies have shown that integrin β1 is capable of regulating members of the 
Rho family of small GTPases (Gimond et al., 1999; Miao et al., 2002; Hirsch et al., 2002; 
Sturge et al., 2002). 
 
Rho Family Proteins in Metastasis 
The activation of the Rho family of small GTPases, namely Rac, Rho, and Cdc42, 
is a critical event in the integrin-mediated regulation of the cellular processes of adhesion, 
migration, and invasion (Miranti and Brugge, 2002; Hynes, 2002).  All Rho GTPases 
have been implicated in the turnover of FACs, a critical step in cell motility.  Subsequent 
to activation, Rho GTPases interact with downstream target proteins to induce specific 
cellular responses:  Rac regulates the polymerization of actin at the cell periphery to 
produce lamellipodia, Rho regulates cell contractility and the assembly of actin stress 
fibers, while activated Cdc42 induces the formation of filopodia (Hall and Nobes, 2000).  
However, during the processes of adhesion, migration, and invasion, crosstalk between 
the Rho GTPases, their isoforms, and their downstream effectors are coordinated in a 
highly complex and not completely understood manner (Schmitz et al., 2000).  Activation 
of appropriate levels, together with temporal and spatial coordination, must be precisely 
regulated in order to achieve normal adhesion and motility (Price and Collard, 2001).  
The balance between Rac, Cdc42, and Rho, as well as the localized activity of these 
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proteins, is essential for the determination of cellular morphology and invasive behavior 
(Evers et al., 2000). 
Integrin signaling subsequent to clustering and activation includes the tyrosine 
phosphorylation and activation of the Epidermal Growth Factor Receptor (EGFR), a 
common upstream effector of the Rho family GTPases, usually activated by the EGF 
(epidermal growth factor) ligand (Moro et al., 1998; Miyamoto et al., 1996).  In fact, 
Rac1 has been shown to be required for the EGF-induced migration of breast carcinoma 
cells (O'Connor and Mercurio, 2001).  Moreover, overexpression of the EGFR in breast 
cancer cells has been shown to increase invasiveness and metastasis, via Rac1 and Cdc42 
(Sturge et al., 2002).  However, evidence shows that the contribution of the Rac1 and 
Cdc42 proteins to tumor cell invasion in breast cancer is not due to genetic mutation 
(Fritz et al., 2002).  Changes in the activity levels of these proteins due to upregulation of 
upstream activators instead has been shown to be responsible for the promotion of tumor 
cell invasiveness (Price and Collard, 2001; Fritz et al., 2002).  Conversely, the 
overexpression of the RhoC gene has been strongly implicated in tumor progression, and 
has been shown to result in a motile and invasive phenotype when overexpressed in 
human mammary epithelial cells (Clark et al., 2000; Kleer et al., 2002).   
To understand the role of Rho GTPases and their correlation to integrin 
expression in metastatic breast cancer, we used isolated variants of the MDA-MB-435 
metastatic breast cancer cell line according to integrin α6 expression and metastatic 
efficiency in the mouse model of experimental metastasis (Mukhopadhyay et al., 1999).  
Data presented here shows that increased α6 integrin protein expression and increased 
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migratory ability toward reconstituted proteins of the basement membrane does correlate 
with increasing metastatic potential.  Moreover, increased Rho and Rac (but not Cdc42) 
activity, as well as increased RhoC protein expression, correlates with an increased 
metastatic morphology and phenotype. Together, these data suggest that increased 
expression of the α6β1 integrin heterodimer contributes to the metastatic phenotype of 
MDA-MB-435 breast cancer cell variants via its effects, direct or indirect, on the activity 
of the small GTPases Rac and Rho.   
  




Variants of the human breast cancer cell line MDA-MB-435, a kind gift from Dr. 
Janet Price (MD Anderson Cancer Center, Houston, TX), were selected according to α6 
expression and metastatic efficiency in the nude mouse model as described in 
(Mukhopadhyay et al., 1999).  Cells were cultured in supplemented minimum essential 
medium (GibcoTM, CA) with 10% fetal bovine serum (Tissue Culture Biologicals, CA), 
and cultured in a humidified 5% CO2 atmosphere at 37°C.  
  
Immunoblotting 
Proteins from total cell lysate were separated by 12% SDS-PAGE gel, transferred 
to a nitrocellulose membrane, and probed with a goat polyclonal anti-a6 integrin 
antibody.  (Santa Cruz Biotech, CA).  Immunoblots were detected with the SuperSignal 
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West Femto-Substrate chemiluminescence kit (Pierce Endogen, IL) and Kodak Biomax 
MR film (Fisher Scientific, TX).  
 
Wound Healing Assay 
Cells were cultured on coverslips until 100% confluency, then stimulated by 
wounding as described in (Nobes and Hall, 1999).  Wound healing assays were 
performed by wounding a confluent monolayer of cells with a sterile 21G11/2 Precision 
GlideTM needle (Becton Dickinson and Co., NJ).  
 
Immunofluorescence Microscopy 
 Cells were cultured on coverslips either until 50% confluency, or until 100% 
confluency.  Cells were either fixed at 50% confluency, or two hours after wounding 
using 4% formaldehyde (Sigma Chemical Corp., MO).  Cells were then permeabilized 
with 0.5% Triton X-100 (Sigma, MO), and blocked with 5% goat serum (GibcoTM, CA)  
and 5% BSA (Sigma Chemical Corp., MO) in PBS.  To visualize F-actin, cells were 
stained with rhodamine phalloidin (Molecular Probes Inc., OR), and a mouse monoclonal 
anti-phosphotyrosine antibody, clone 4G10 (Upstate Biotechnology, NY), followed by 
FITC-conjugated goat anti mouse IgG (ICN Biomedicals Inc., CA) to visualize the focal 
adhesions.  Cells were imaged using an Olympus upright fluorescence microscope, then 
overlayed with Spot Advanced digital camera software (Diagnostic Instruments Inc., MI).  
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Constructs and Transfections 
 Rac1 mutant cDNA (myc-Rac1(T17N)) and Cdc42 mutant cDNA (myc-
Cdc42(T17N)) were generous gifts from Dr. Gary Bokoch of the Scripps Institute (La 
Jolla, CA).  Rac3 mutant cDNA (myc-Rac3(T17N)) was a generous gift from Dr. Ulla 
Knaus of the Scripps Institute (La Jolla, CA).  Mutant Rac and Cdc42 mutant cDNAs 
were digested out of the pRK5myc vector and inserted in to the multiple cloning site of 
the pIRESneo2 vector (Clontech, CA). 
 PIRESneo2 vector alone, or vectors encoding myc-tagged Rac1(T17N) or 
Cdc42(T17N) were transfected into cell variants using Lipofectamine Plus Reagent 
(GibcoTM, CA).  Maximal expression was achieved 24-48 hours post transfection. 
 
Haptotaxis Migration Assays 
 Cell migration and invasion assays were performed as described in (Klemke et al., 
1998).  Briefly, modified Boyden chambers (tissue culture treated, 6.5 mm diameter, 
10µm thickness, 8 µm pores, Transwell®, Costar Corp., Cambridge, MA) were coated on 
the underside, of the membrane with matrigel (Fisher Scientific, TX), or 50 µg/ml 
laminin (Gibco BRL, MD) overnight at 4° and then placed into a trans-well.  Serum 
starved cells (105 cells) were added to the upper surface of each migration chamber and 
allowed to migrate to the underside of the membrane for 4 hours.  The non-migratory 
cells on the upper membrane surface were removed with a cotton swab, and the 
migratory cells attached to the bottom surface of the membrane stained with propidium 
iodide (PI) (CalBioChem-Novabiochem Corp., CA).  Briefly, cell were fixed and 
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permeabilized with 70% ethanol, then incubated with PI in 1XPBS (phosphate buffered 
saline).  The number of migratory cells per membrane was counted with an Olympus 
upright fluorescence microscope with a 40x objective.  Non-specific migration as 
measured on chambers with no matrigel or laminin was subtracted. 
 
Toxin B Inhibition 
 Clostridium difficile Toxin B was purchased from Calbiochem (CA).  Cells were 
treated with 2 ng/ml Toxin B for 24 hours before being subjected to haptotaxis assay.   
   
Guanine Nucleotide Binding 
Cell lysates were incubated for 15 min at 30 °C in the presence of 10 mM EDTA 
and 100 µM GTPγS or 1 mM GDP to facilitate nucleotide exchange as described in 
(Knaus et al., 1992).  The loading reaction was stopped by addition of 60 mM MgCl2. 
 
Rac, Cdc42, and Rho Activity Assays 
 Rac and Cdc42 activity assays were performed as described in (Benard et al., 
1999), Rho activity assays were performed as described in (Ren and Schwartz, 2000), 
with minor modifications.  Briefly, cells were washed twice with 1X PBS, lysed with 1X 
ice cold lysis buffer, and scraped from the plate.  Lysates were then incubated at 4° for 1 
hour with 10 µg of PAK-PBD Protein GST Beads (Cytoskeleton Inc., CO) for Rac and 
Cdc42, or Rhotekin-RBD Protein GST Beads (Cytoskeleton Inc., CO) for Rho activity.  
The bead pellet was then washed once with wash buffer containing 1% Nonidet P-40 
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(Calbiochem, CA) and twice without Nonidet P-40.  The bead pellet was finally 
suspended in 20 µl Laemelli sample buffer.  Proteins from total cell lysate, as well as the 
bead pellet, were separated by 10% SDS-PAGE gel, transferred to a nitrocellulose 
membrane, and blotted for the appropriate GTPase using a monoclonal anti-Rac (clone 
32A8) antibody (Upstate Biotechnology, NY), a rabbit polyclonal anti-Rho -A, -B, -C 
antibody (Upstate Biotechnology, NY), a mouse monoclonal anti-Cdc42 (clone 44) 
antibody (Transduction Laboratories, CA), or a goat polyclonal anti-RhoC antibody 
(Santa Cruz Biotechnology, CA).  Immunoblots were detected with the SuperSignal West 
Femto-Substrate chemiluminescence kit (Pierce Endogen, IL) and Kodak Biomax MR 




α6 Integrin expression among the panel of metastatic variants. 
 The isolated MDA-MB-435 cell variants were found to express differential levels 
of α6 integrin, as measured by flow cytometry (Mukhopadhyay et al., 1999).  To confirm 
this result, total endogenous protein expression of α6 integrin was measured by western 
blot analysis.  Increasing levels of α6 integrin were found to correlate with increasing 





Motile morphology of MDA-MB-435 metastatic variants correlates with metastatic 
efficiency. 
To understand the role of the Rho GTPases in metastatic breast cancer, we  used 
isolated variants of the MDA-MB-435 metastatic breast cancer cell line that had been  
cycled through the nude mouse model of experimental metastasis to determine metastatic 
efficiency (Mukhopadhyay et al., 1999).  The results identified MDA-MB-435α6HG6 as 
the variant most likely to produce distant metastasis, followed by the parental MDA-MB-
435, then MDA-MB-435α6LF9, and finally MDA-MB-435Br1 (Mukhopadhyay et al., 
1999).     
An invasive cellular phenotype can be indicative of metastatic behavior (Schmitz 
et al., 2000).  Rac-induced membrane ruffles, or lamellipodia, have been shown not only 
to be important structures in cellular motility, but have also been shown to play a key role 
in invasion with respect to metastatic progression (Ridley, 2001; Condeelis et al., 2001).  
Rac-induced lamellipodia contain cell-substratum contacts, or focal adhesions, and 
aberrant focal adhesion expression has also been associated with malignant progression 
(Schlaepfer et al., 2004).  Therefore, we investigated the correlation between cytoskeletal 
phenotype, focal adhesion contacts, and metastatic efficiency.  Our data shows a direct 
correlation between increased lamellipodia expression and increased metastatic efficiency 
(Figure 3.2).  The most metastatic variant, MDA-MB-435α6HG6, exhibits a strikingly 
different phenotype than the other variants, including an increased number of focal 
adhesions as well as a cross-linked actin network.  In fact, increasing focal adhesion 
expression also correlates with increasing metastatic efficiency (Figure 3.3a).  However, 
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individual MDA-MB-435α6HG6 (most metastatic) cells were 1.5 times larger than other 
variants (data not shown).  Thus, the data was compiled as focal adhesions per cell area 
(Figure 3.3b).  This correlation between lamellipodia, focal adhesions, and metastatic 
potential strongly suggests an increase in Rac activity among those variants with 
increased metastatic efficiency. 
 
Subcellular distribution of focal adhesions and filamentous actin subsequent to 
cellular polarization during the wound healing response.  
Actively motile cells polarize to form leading edge lamellipodia toward the 
direction of migration, which is one of the initial steps of intravasation (Condeelis et al., 
2001).  To induce cellular polarization, the four cell variants were stimulated by 
wounding a confluent monolayer to produce a motile response.  The cells were then 
immunostained with rhodamine phalloidin to visualize f-actin structures and an anti-
phosphotyrosine to visualize focal adhesions.  Focal adhesions can be classified into two 
distinct categories:  smaller, more compact focal complexes and longer, stress-fiber 
associated focal contacts (Zamir and Geiger, 2001).  Focal complexes, induced by the 
activation of the small GTPase Rac, are found at the leading edge of lamellipodia and are 
responsible for the generation of strong propulsive forces in migrating fibroblasts (Nobes 
and Hall, 1995; Clark et al., 1998; Rottner et al., 1999; Beningo et al., 2001; Clark et al., 
1998; Rottner et al., 1999; Beningo et al., 2001).  Subsequent to their formation, focal 
complexes will develop into focal contacts as a consequence of the activation of Rho 
(Clark et al., 1998; Rottner et al., 1999).   
 62
In this study, we find that cellular polarization in the more metastatic variants 
tends to elicit wider membrane ruffles as well as more cell area invasion into the wound 
space (Figure 3.4, upper panels).  Upon stimulation by wounding, the most metastatic 
MDA-MB-435α6HG6 variant demonstrates the most invasive phenotype, exhibiting 
marked lamellipodial invasion into the wound space (Figure 3.4, upper left panel).  The 
parental cell line, MDA-MB-435, also highly metastatic, exhibits a comparatively 
invasive phenotype to the MDA-MB-435α6HG6, but with smaller lamellipodia and is 
consequently less invasive into the wound space (Fig 3.4, upper right).  The two 
remaining variants, MDA-MB-435α6LF9 and MDA-MB-435Br1, exhibit similar 
phenotypes to each other in response to wounding (Figure 3.4, lower panels).  The cell-
surface F-actin containing structures of these cell variants extending into the wound space 
are more elongated and slender than the wider lamellipodia of the more metastatic strains.  
In addition, the points of contact between ECM and cell surface of these less metastatic 
variants appear to be mature focal contacts, indicating a more stationary cell and a less 
motile phenotype (Figure 3.4).  The same points of contact in the more metastatic 
variants appear to be more like nascent focal adhesions, indicating a more motile and 
invasive phenotype (Figure 3.4).   
 
Migratory phenotype of MDA-MB-435 variants correlates with metastatic 
efficiency.  
Subsequent to the epithelial to mesenchymal transition, cells must first migrate 
away from the primary tumor through the basal lamina to begin the process of 
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establishing sites of secondary tumorigenesis.  Therefore, increased cell migration in 
malignant cells is thought to be closely linked to invasion and metastasis (Ridley et al., 
2003).  Upon investigation into migratory behavior of the cell variants, we found a 
correlation between increased metastatic potential and increased migration (Figure 3.5a).  
Because the Rho family of small GTPases, namely Rac, Rho, and Cdc42, are essential to 
cell motility, we used Clostridium difficile toxin B to inhibit the Rho family in these cell 
variants.  Subsequent to treatment with toxin B, the most metastatic variant MDA-MB-
435α6HG6 exhibited a 2-fold decrease in migration to basal lamina, while the others 
exhibited a substantial, but not significant, decrease in migration (Fig 3.5b).   
 
Increased Rac and Rho activity directly correlate with metastatic potential.  
 Increases in activity levels of the Rho proteins Rho, Rac, and Cdc42 have been 
shown to be accountable for the promotion of tumor cell invasiveness (Fritz et al., 2002; 
Price and Collard, 2001). Therefore, we investigated the activity levels of these proteins 
in all MDA-MB-435 metastatic variants.  To determine the relative amounts of activated 
Rho in the variant panel, the RBD-GST activity assay was used (Ren and Schwartz, 
2000).  Total endogenous Rho protein expression varied among the variants, with the 
more metastatic variants expressing more endogenous Rho protein than the less 
metastatic variants.  However, increased Rho protein activity was found to directly 
correlate with increased metastatic potential (Figure 3.6a).  Loading cell lysates with a 
non-hydrolyzable GTP analog, GTPγS, showed a differential binding ability of the Rho 
proteins among the four variants.  This result could be due to differential endogenous 
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protein expression of the different Rho isoforms, RhoA and RhoC.  In fact, endogenous 
expression of RhoA was equal among the variants, but endogenous RhoC expression was 
greatly increased in the most metastatic variant (Figure 3.6b).  
To determine the relative amounts of activated Rac and Cdc42 in the variant 
panel, we used the PBD-GST activity assay (Benard et al., 1999).  While total 
endogenous Rac protein expression remains equal among the cell variants, Rac protein 
activity directly correlates with increased metastatic potential (Figure 3.7a).  Loading cell 
lysates with a non-hydrolyzable GTP analog, GTPγS, showed a relatively equal GTP-
binding ability of the Rac protein among the four variants.  Therefore, all Rac expressed 
in the variants of the metastatic panel can be activated to the same extent.  Thus, 
endogenous activators of Rac appear to have increased activity in the more metastatic cell 
variants.  Endogenous Cdc42 protein expression differed among the variants:  the more 
metastatic variants expressed higher levels of endogenous Cdc42 than the less metastatic 
variants (Figure 3.7b).  However, no active Cdc42 protein could be detected.  Again, 
GTPγS loading showed the ability of the Cdc42 proteins to bind GTP and become active.   
 
Blocking Cdc42 activation has no significant effect on cell migration. 
Hyperactive Cdc42 has been implicated in tumor cell invasion due to its effects 
on the actin cytoskeleton (Bouzahzah et al., 2001).  Additionally, EGFR overexpression 
has been shown to be responsible for this hyperactivation (Sturge et al., 2002).  To 
determine a role for Cdc42 in the migration of highly metastatic cells, we expressed 
vector alone and a dominant negative myc-Cdc42(T17N) construct in the highly 
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metastatic MDA-MB-435α6HG6 cell variant and subjected both to a migration assay.  
We found that Cdc42(T17N) did not significantly inhibit migration as compared to the 
vector alone control (Figure 3.8a).  However, when we expressed vector alone, dominant 
negative Rac1(T17N) or dominant negative Rac3(T17N), we found a significant 
inhibition (p value>0.01) of migration as compared to the vector control (Figure 3.8b).  
Therefore, Rac activity appears to be essential for the migration of highly metastatic 




The present study illustrates a correlation between the activated Rho proteins Rac 
and Rho, the invasive phenotype, and the increased metastatic capability of the human 
breast cancer cell variants of the MDA-MB-435 cell line.  Rho proteins have been both 
directly and indirectly associated with the transformation from primary tumor cells to 
highly motile and invasive malignant cells (Kleer et al., 2002; Silva et al., 2000; 
Bourguignon et al., 2000; Bouzahzah et al., 2001).  Invasive phenotypes, including 
aberrant focal adhesions and increased numbers of lamellipodia, have also been 
associated with metastatic progression and increased cellular motility (Kassis et al., 2001; 
Ridley, 2001; Sahai and Marshall, 2002).   
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Migratory Phenotype and Metastatic Progression 
It has been shown that the intravasation of cancer cells begins with directed 
lamellipod extension (Condeelis et al., 2001).  We confirm this finding by demonstrating 
lamellipod extension directly into the wound space by the more metastatic MDA-MB-
435 variants.  In addition, we demonstrate that the overall size of the lamellipod, as well 
as the quantity of overall F-actin staining, directly correlates with increasing metastasis.  
Focal complexes have been shown to be associated with both lamellipodia and the 
generation of strong propulsive forces in migrating fibroblasts (Nobes and Hall, 1995; 
Clark et al., 1998; Rottner et al., 1999; Beningo et al., 2001).  Again, we validate these 
observations by demonstrating that in cells growing in serum, increasing focal adhesion 
number per cell area directly correlates with increasing metastatic potential.  This finding 
suggests that cells exhibiting larger lamellipodia will migrate and invade in greater 
numbers than those with the more slender uropodia containing less focal complexes.  
Indeed, we find this to be the case across reconstituted basement membrane.  As 
predicted, the more metastatic cells, or those presenting larger lamellipodia and more 
focal complexes, invaded and migrated through reconstituted basal lamina faster than 
those forming slender uropodia upon stimulation.  In conclusion, the more metastatic 
cells tend to exhibit clear morphological as well as physiological differences from the 
less metastatic cells.     
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Rac and Cdc42 Activation and Metastatic Progression 
Increased activation of the small GTPases Rho, Rac, and Cdc42 have been 
strongly implicated in malignant progression (Schmitz et al., 2000; Evers et al., 2000; 
Jaffe and Hall, 2002; Steeg, 2003).  Several studies have shown that increased Rac1 or 
RhoA,C signaling via increased protein activation can promote the acquisition of an 
invasive phenotype (Price and Collard, 2001; Bourguignon et al., 2000; Otsuki et al., 
2001; Zhuge and Xu, 2001).  In the present study, we corroborate these findings by 
demonstrating that metastatic potential directly correlates with levels of Rac activation.  
In addition, we substantiate the idea that increased Rac activity correlates with increased 
focal complex and lamellipodia formation, as well as increased migration across basal 
lamina.  However, we could not find the same correlation with the small GTPase Cdc42.  
The disregulation of Cdc42 has been implicated in tumor cell invasion due to its effects 
on the actin cytoskeleton, via its downstream effector WASP, which activates actin 
nucleation by stimulating Arp2/3 (Sturge et al., 2002).  Several studies have implicated 
Cdc42 in regulating the initial cell polarization necessary for directed motility (Srinivasan 
et al., 2003; Wedlich-Soldner et al., 2003).  In the present study, we found that levels of 
activated Cdc42 were so low as not to be detected by our techniques.  Although in 
opposition to other findings, this data does not support a direct Cdc42-mediated role for 
cell polarization during the migration of breast cancer cells.  Moreover, Cdc42 is known 




Increased α6 Integrin Expression and Rho GTPase Activation is Linked to 
Increased Metastatic Potential 
Because these variants were sorted according to α6 integrin expression, and 
increased α6 integrin expression correlates with metastatic capability, it is possible that 
aberrant α6 integrin expression is responsible for the variations in metastatic capability of 
these cells (Mukhopadhyay et al., 1999; Shimizu et al., 2002; Friedrichs et al., 1995; 
Tagliabue et al., 1998).  In MDA-MB-435 cell lines, β1 integrin dimerizes with α6 
integrin to form the transmembrane heterodimer that binds laminin (Wewer et al., 1997).  
Significantly, both the overexpression and stimulation of β1 integrin have been found to 
increase Rac activity and lamellipodia formation (Sturge et al., 2002; Miao et al., 2002).  
Moreover, it has been shown that integrin clustering and subsequent Rac activation can 
lead to invasion via the GEF Vav2 (Cho and Klemke, 2000).  It has also been 
demonstrated that Vav2 is a crucial downstream component in EGFR- and PI 3-kinase-
dependent Rac activation upon integrin-mediated cell adhesion (Marcoux and Vuori, 
2003).  Therefore, it is possible that increased a6b1 integrin expression in out panel of 
metastatic variants is causing the upregulation of Rac activation via the GEF Vav2.  
However, we present no direct evidence for this activation, and thus required further 
experimentation.  
It is possible to block the activation α6 integrin, and subsequently α6β1 integrin 
signaling, with the α6 integrin-blocking monoclonal antibody GoH3 (Jiang et al., 2001; 
Dangerfield et al., 2005).  To show that blocking α6β1 adhesion and subsequent signaling 
is responsible for the Rho GTPase activation, the cell variant with the highest endogenous 
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Rac activation should be used (MDA-MB-435α6HG6).  Rac and Rho activity assays 
should be performed subsequent to α6 integrin blocking.  If α6β1 integrin is responsible 
for Rho protein activation, a decrease in Rho and Rac activity should be seen.  
Furthermore, GEF activation assays should also be performed to determine the activation 
pathway linking α6β1 integrin engagement to Rho protein activation.      
 
Rho Activation in Metastatic Progression 
  The role of the Rho protein in cancer cell invasion is somewhat controversial.  
Some studies find that overexpression of Rho has little effect, while others have 
demonstrated a positive role for Rho in tumor cell migration and invasion (Stam et al., 
1998; Itoh et al., 1999; O’Connor et al, 2000).  The reason for this inconsistency is based 
on the fact that active Rho performs two roles regarding migration:  Rho promotes stress 
fiber formation while at the same time facilitates cell body contraction (Ridley, 2001).   
Therefore, cellular effects caused by the disregulation of Rho is dependent on cell type, 
and tends to reflect the basal levels of stress fibers and focal adhesions found within the 
cell (Cox and Huttenlocher, 1998; Ridley, 2001).  RhoC, a Rho isoform associated 
primarily with the contractility of the actin cytoskeleton, has recently been identified as 
an oncogene in breast cancer that can promote the metastatic phenotype (van Golen et al., 
1999).  Although total protein expression of Rho as detected with an antibody to the -A, -
B, and –C, isoforms demonstrates equal expression across all cell strains, western 
blotting with a RhoC-specific antibody revealed increased endogenous RhoC expression 
in the more metastatic variants, while blotting with a RhoA-specific antibody detected 
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little difference among the variants.  Activity assays detected increased overall Rho 
activity in the more metastatic variants, but this variation could possibly be due to the 
activity of RhoC, and not Rho -A or -B.  Due to the evidence that the increased activation 
of Rac and Rho correlates with increased invasion and metastasis, we substantiate the 
idea that migratory behavior, and subsequent tumor cell invasion, is a result of a 
reciprocal balance between Rac and Rho activities (Evers et al., 2000). 
 
Conclusion   
This study, for the first time, demonstrates a direct correlation between increased 
Rac and Rho activity and increased metastatic potential.  Moreover, for the first time, this 
study suggests a correlation between the increased expression of α6β1 integrin, increased 
Rac activity, and increased RhoC expression.  It is clear from the results that all of these 
factors increase migratory and adhesive properties in vitro.  However, whether the 































Figure 3.1.  α6 Integrin expression in MDA-MB-435 metastatic variant panel.   
Whole cell lysates of MDA-MB-435α6HG6, MDA-MB-435, MDA-MB-435α6LF9, and 
MDA-MB-435Br1 were subjected to SDS-PAGE followed by western blot analysis for 
integrin α6.  Equal loading of lanes was maintained by lysing equal numbers of cells per 
















Figure 3.2.  Characterization of cytoskeletal structures and focal adhesion 
distribution in MDA-MB-435 metastatic variants.   Each of the MDA-MB-435 
metastatic variants were plated onto glass coverslips. Actin was then visualized with 
rhodamine phalloidin and focal adhesions were visualized with an anti-p-tyro antibody 









Figure 3.3.  Quantitation of focal adhesion distribution in MDA-MB-435 metastatic 
variants.  (a) Focal adhesions were counted on a total of 100 individual cells per variant.  
Data shown are the average of 50 cells per variant, with the bars representing standard 
error of the mean, and are representative of three independent experiments. (b) Cell area 
was measured on 50 individual cells per variant using Spot Digital Camera Software.  
Focal adhesion number was divided by cell area and plotted on the y-axis.  Bars represent 










Figure 3.4.  Migratory morphology of MDA-MB-435 variants.  Cells were grown to 
confluent monolayers then wounded to stimulate the motile response.  Dotted white line 
represents the wounding site.  Actin was then visualized with rhodamine phalloidin and 
focal adhesions were visualized with an anti-phosphotyrosine antibody followed by an 






Figure 3.5.  Haptotaxis assays of MDA-MB-435 metastatic variants.  (a) Each variant 
was adjusted to 500,000 cells and applied to Transwell chambers in a basement 
membrane haptotaxis assay.  Cells migrating to the underside of the chamber were 
stained with PI and counted under (400X).  Bars represent +/- SEM.  Data is 
representative of three independent experiments.  (b) Cells either treated with Toxin B 
(Toxin B) or untreated (untreated) were subjected to a haptotaxis assay.  Each group was 
adjusted to equal concentrations and applied to Transwell chambers.   Cells migrating to 
the underside of the chamber were stained with PI and counted under (400X).  Bars 






Figure 3.6.  Rho expression and activity in MDA-MB-435 metastatic variants. Whole 
cell lysates of all variants were subjected to SDS-PAGE followed by western blot 
analysis for total Rho expression using an anti-Rho (A,B,C) antibody, an anti-RhoA 
specific or an anti-RhoC specific antibody.  Rho activity was assayed using the GST-
RBD activity assay.  A non-hydrolyzable GTP analog, GTPγS, was used as the positive 
control; GDP alone was used for the negative control. Equal loading of lanes was 
maintained by performing a total protein assay and is confirmed by western blot analysis 
for total actin.  Results are representative of three to five independent experiments. 
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Figure 3.7.  Rac and Cdc42 activity in MDA-MB-435 metastatic variants.  Whole cell 
lysates of all variants were subjected to SDS-PAGE followed by western blot analysis for 
total Rac (a) using an anti-Rac antibody and total Cdc42 (b) using an anti-Cdc42 
antibody.  Rac and Cdc42 activity were assayed using the PAK-PBD activity assay.  A 
non-hydrolyzable GTP analog, GTPγS, was used as the positive control; GDP alone was 
used for the negative control. Equal loading of lanes was maintained by performing a 
total protein assay and is confirmed by western blot analysis for total actin.  Results are 
representative of three to five independent 
experiment
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Figure 3.8.  Migration of MDA-MB-435α6HG6 cells expressing dominant negative 
Rac and Cdc42 mutants.  (a) MDA-MB-435α6HG6 cells transiently expressing vector 
alone or myc-Cdc42(T17N) were subjected to a haptotaxis assay.  Cells migrating to the 
underside of the membrane were stained with PI and counted under (400X).  Bars 
represent (+/-) SEM.  Equal loading was confirmed by a total actin blot, myc-
Cdc42(T17N) expression confirmed by western blot with anti-myc. (b)  MDA-MB-
435α6HG6 cells transiently expressing vector alone, myc-Rac1(T17N), or myc-
Rac3(T17N) were subjected to a haptotaxis assay.  Bars represent (+/-) SEM, equal 
loading was confirmed by total actin blot.  Myc-Rac1(T17N) and myc-Rac3(T17N) 
expression were confirmed by both anti-Rac and anti-myc.  An asterix indicates a 
statistically significant difference compared to the control, vector alone, as determined by 
a Student’s t-test (P<0.05). 
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4.  Rac1 and Rac3 Activation is Involved in the Invasive 




Cancer metastasis is a multi-faceted process requiring the disregulation of 
numerous signaling pathways, including those associated with cell adhesion and motility.  
The initial steps of metastasis require the acquisition of a motile phenotype in order to 
traverse tissue boundaries, while the later stages require the activation of cell adhesion to 
facilitate the extravasation of malignant cells (Sahai and Marshall, 2002).  Activation of 
the Rho family GTPases Rac and Cdc42 is a critical event in the integrin and growth 
factor-mediated regulation of cellular migration and adhesion, which implicates the 
hyperactivation of these proteins in the progression of metastatic disease (Miranti and 
Brugge, 2002). 
  
Rac and Cdc42 in Breast Cancer Metastasis 
The activation of Rac and Cdc42 is critical for initiating cell motility and 
adhesion via the dynamic turnover of cell-substratum contacts (focal adhesions) and the 
nucleation of actin monomers leading to the assembly of actin filaments necessary for 
cell movement (Hynes, 2002).  Activation of the appropriate levels of these proteins, 
together with temporal and spatial coordination, must be precisely regulated in order to 
achieve normal cellular function (Price and Collard, 2001).  Aberrant Rac and Cdc42 
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activity have been recently associated with invasive and malignant behavior in a variety 
of cell types, including hepatocarcinoma, breast carcinoma, and melanoma (Lee et al., 
2004; Bouzahzah et al., 2001; Uhlenbrock et al., 2004).  However, breast tissue sample 
analysis has shown that the contribution of the Rac and Cdc42 proteins to tumor cell 
invasion in breast cancer is not due to genetic mutation, but is due instead to changes in 
the activity levels of these proteins caused by hyperactivation of upstream activators 
(Fritz et al., 2002; Price and Collard, 2001).  Yet, a direct correlation between Rac and 
Cdc42 protein activity states and metastatic progression in human breast cancer remains 
to be demonstrated. 
  
The Rac-like Subfamily of Rho GTPases 
The Rac-like subfamily of Rho GTPases includes Rac1, the myeloid-lineage 
specific Rac2, and the subsequently cloned Rac3 protein (Haataja et al., 1997).  Because 
Rac2 is found only in myeloid-lineage cells, only Rac1 and Rac3 are thought to be 
involved in breast cancer metastasis.  Exhibiting a 92% identity to Rac1, Rac3 differs 
from Rac1 in the C-terminus, a region essential for subcellular localization, and in the 
insert region, a region necessary for regulatory protein binding (Haataja et al., 1997; 
Chou and Blenis, 1996).  In fact, some differences have been found between Rac1 and 
Rac3 function.  For example, Rac3 has been found to be more highly expressed in neural 
tissue than is Rac1 (Bolis et al., 2003).  This differential distribution is thought to support 
a role for Rac3 specifically in the remodeling of Purkinje cell neuritic terminals at the 
time of synaptogenesis (Bolis et al., 2003).  Rac3 has been found to interact with the 
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integrin-binding protein calcium and integrin-binding (CIB) protein, a protein with which 
neither Rac1 nor Rac2 interact (Haataja et al., 2002).  This differential binding is thought 
to implicate Rac3 specifically in integrin-associated cytoskeletal reorganization during 
αIIBβ3-mediated adhesion (Haataja et al., 2002).  Furthermore, Rac3, but not Rac1, was 
found to control proliferation in breast cancer cells (Mira et al., 2000).   
However, a direct role for Rac3 in breast cancer invasion and metastasis has never been 
substantiated.   
To further understand the molecular mechanisms of the small GTPases Rac and 
Cdc42 in human breast cancer, we used a panel of metastatic variants derived from the 
parental MDA-MB-435 breast cancer cell line (Mukhopadhyay et al., 1999).  Within this 
panel, we found a direct correlation between both the invasive phenotype and enhanced 
migratory ability and increased metastatic potential (Chapter 3).  Moreover, we found 
that increased Rac, but not Cdc42, activation correlated with increased metastatic 
potential (Chapter 3).   
Previously, Rac1 was shown to play a critical role in rat mammary tumor cell 
growth and metastasis in vivo (Bouzahzah et al., 2001).  To establish a role for both Rac1 
and Rac3 in human breast cancer, we carried out a comparative study between the two 
isoforms.  Dominant active Rac1 or Rac3 mutants were expressed in the least metastatic 
cell variant of our panel, while dominant negative Rac1 or Rac3 mutants were expressed 
in the most metastatic cell variant.  Dominant active Rac expression of either isoform 
resulted in an aggressive phenotype, as well as significant increases in adhesion, 
migration, and invasion.  Conversely, dominant negative expression of either isoform 
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resulted in significant decreases in adhesion, migration, and invasion.  Moreover, low 
metastatic cell lines stably expressing dominant active Rac1 or Rac3 proteins caused 
metastatic lesions in the lung of the nude mouse, as compared to the control.  Highly 
metastatic cell lines stably expressing dominant negative Rac 1 or Rac3 blocked 
metastasis to the lung of the nude mouse.  Taken together, these data suggest a direct role 
for both Rac1 and Rac3 proteins in the metastatic progression of human breast cancer. 
 
4.2 Materials and Methods 
 
Cell Culture 
The human breast cancer cell lines variants MDA-MB-435α6HG6 and MDA-
MB-435Br1 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (GibcoTM, 
CA) with 10% fetal bovine serum (FBS) (Tissue Culture Biologicals, CA) and cultured in 
a humidified 5% CO2 atmosphere at 37°C.  
 
DNA Constructs, Transfections, and Stable Cell Selection 
 Rac1 mutant cDNA (Myc-Rac1(G12V) and Myc-Rac1(T17N))  were generous 
gifts from  Dr. Gary Bokoch of the Scripps Research Institute (La Jolla, CA).  Rac3 
mutant cDNA (Myc-Rac3(G12V) and Myc-Rac3(T17N)) were generous gifts from Dr. 
Ulla Knaus of the Scripps Institute (La Jolla, CA).  Mutant Rac cDNAs were digested out 
of the pRK5myc vector and inserted into the multiple cloning site of the pIRESneo2 
vector (Clontech). 
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 pIRESneo2 vector alone, or vectors encoding Myc-Rac1(G12V), Myc-
Rac1(T17N), Myc-Rac3(G12V), or Myc-Rac3(T17N) were transfected into cell variants 
using Lipofectamine Plus Reagent (GibcoTM, CA).  Maximal expression was achieved 
24-48 hours post transfection. 
 Cells expressing constructs were selected in 1 mg/ml G418 Sulfate (Fisher 
Scientific, TX) for 3 weeks.  Subsequent to selection, colonies were picked and 
subcloned in 1mg/ml G418 Sulfate for an additional 3 weeks. 
 
Rac Activity Assay 
 Rac activity assays were performed as described in (Benard et al., 1999), with 
minor modifications.  Briefly, cells were washed twice with 1X PBS, lysed with 1X ice 
cold lysis buffer, and scraped from the plate.  Lysates were then incubated at 4° for 1 
hour with 10 µg of PAK-PBD Protein GST Beads (Cytoskeleton Inc., CO) for Rac 
activity.  The bead pellet was then washed once with wash buffer containing 1% Nonidet 
P-40 (Calbiochem, CA) and twice without Nonidet P-40.  The bead pellet was finally 
suspended in 20 µl Laemelli sample buffer.  Proteins from total cell lysate, as well as the 
bead pellet, were separated by 12% SDS-PAGE gel, transferred to a nitrocellulose 
membrane, and blotted for the appropriate GTPase using a monoclonal anti-Rac (clone 
32A8) antibody (Upstate Biotechnology, NY) or an rabbit polyclonal anti-actin antibody 
(Sigma, MO).  Immunoblots were detected with the SuperSignal West Femto-Substrate 
chemiluminescence kit (Pierce Endogen, IL) and Kodak Biomax MR film (Fisher 
Scientific, TX).  
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Immunofluorescence Microscopy 
 Cells in culture were placed on glass coverslips, fixed in 3.7% formaldehyde 
(Sigma Chemical Corp., MO), permeabilized with 0.5% Triton X-100 (Sigma, MO), and 
blocked with 5% goat serum (GibcoTM, CA) and 5% bovine serum albumin (BSA) 
(Sigma Chemical Corp., MO).  Cells were then stained with rhodamine phalloidin 
(Molecular Probes, OR) to visualize F-actin, and a mouse monoclonal anti-
phosphorylated tyrosine antibody, clone 4G10 (Upstate Biotechnology, NY), followed by 
FITC-conjugated goat anti mouse IgG (ICN Biomedicals Inc., CA) to visualize focal 
adhesions.  Cells were imaged with either an Olympus upright fluorescence microscope 
or an inverted confocal microscope with fluorescence and DIC capabilities.  Images were 
overlayed with Spot Advanced digital camera software (Diagnostic Instruments Inc., MI). 
 
Adhesion Assays 
 Cell adhesion assays were performed according to (Klemke et al., 1998).  Briefly, 
glass coverslips (Fisher Scientific, TX) were coated with laminin (Gibco BRL, MD).  
Proteins were allowed to bind over night at 4° before the coverslips were blocked for 1 
hour with 1% heat-denatured bovine serum albumin (BSA) (Sigma Chemical 
Corporation, MO) in 1X PBS.  Cells (105) were added to the wells and allowed to adhere 
for 15 minutes.  Non-adherent cells were removed, and the adherent cells were fixed in 
3.7% formaldehyde (Sigma Chemical Corp., MO).  The number of cells per coverslip 
was counted with an Olympus upright microscope with a 40x phase contrast objective.  
 85
Nonspecific cell adhesion as measured on poly-L-lysine coated coverslips has been 
subtracted.   
 
Haptotaxis Migration and Invasion assays 
 Cell migration and invasion assays were performed as described in (Klemke et al., 
1998).  Briefly, modified Boyden chambers (tissue culture treated, 6.5 mm diameter, 
10µm thickness, 8 µm pores, Transwell®, Costar Corp., Cambridge, MA) containing 
polycarbonate membranes were coated with matrigel (Fisher Scientific, TX) or laminin 
(Gibco BRL, MD) on the underside of the membrane (migration), or the upperside of the 
membrane (invasion).  For invasion assays, cells chemotracted to media supplemented 
with 10% fetal bovine serum (FBS) (Tissue Culture Biologicals, CA).  Serum starved 
cells (106 cells) were added to the upper surface of each migration chamber and allowed 
to migrate to the underside of the membrane for 4 hours (migration) or 24 hours 
(invasion).  The non-migratory cells on the upper membrane surface were removed, and 
the migratory cells attached to the bottom surface of the membrane were stained with 
propidium iodide (CalBioChem-Novabiochem Corp., CA).  For PI staining, cells were 
fixed and permeablized in 70% ethanol and then incubated with 40 µg/mL PI in 1X PBS.  
The number of migratory cells per membrane was counted with an Olympus upright 
fluorescence microscope with a 40x objective for migration assays and a10x objective for 
invasion assays.  Non-specific migration as measured on chambers with no chemotractant 
has been subtracted.   
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Flow Cytometry  
Stable cell lines were harvested from culture with trypsin, fixed and permeablized 
with 70% ethanol, and stained with PI for cell cycle analysis.  Analysis was performed on 
a Coulter Epics Elite Flow Cytometer (Miami, FL) and analyzed by MultiCyle DNA 
analysis software (Phoenix Flow Systems, San Diego, CA). 
 
Nude Mouse Model of Experimental Metastasis 
 Female athymic nude mice were purchased from Charles River Laboratories 
(Wilmington, MA) and maintained in specific pathogen-free-barrier animal facility 
approved by the American Association for Accreditation of Laboratory Animal Care.  
The mice were used for experiments at 7-8 weeks of age.  Stable MDA-MB-435 cell 
variants expressing mutant Rac isoforms were harvested, resuspended in 1X sterile PBS, 
and injected subcutaneously into the mammary fat pad on the lower left side of the mouse 
at a concentration of 2x106 per 100 µL.  Tumors were measured with calipers once a 
week until the tumor reached 1.5 cm in diameter, or until the mouse became ill.  The 
mouse was then euthanized in accordance with protocols approved by the Institutional 
Animal Care and Utilization Committee under guidelines from the Panel on Euthanasia, 
the American Association of Veterinary Medicine. 
  
India Ink Lung Metastasis Assay 
 The lung was removed from the animal subsequent to euthanization and injected 
through the bronchus with a 15% India ink solution in PBS to saturation using a 28.5 
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gauge needle and 10 ml syringe.  The lung was then suspended in Fekete’s destaining 
solution as described in (Watts and Kennedy, 1998).  The staining procedure results in a 
clear distinction between tumor foci (white) and normal lung tissue (black) on visual 
analysis.  The lung tumors were quantitated and measured with calipers under a 4X 




Characterization of mutant Rac stable cell lines. 
 All cell lines constructed are listed in Figure 4.1a.  Low metastatic MDA-MB-435 
variant MDA-MB-435Br1 was stably transfected with vector alone, myc-tagged 
Rac1(G12V), or myc-tagged Rac3(G12V).  Highly metastatic MDA-MB-435 variant 
MDA-MB-435a6HG6 was stable transfected with vector alone, Rac1(T17N) or 
Rac3(T17N).  For all of these cell lines, total Rac expression, as well as total Rac activity, 
was assayed.  Total Rac protein expression is increased 2-fold in the stable MDA-MB-
435Br1 dominant active mutants, as compared to the control.  Moreover, Rac activity is 
greatly increased in the stable dominant active Rac mutant cell lines as compared to the 
vector control (Figure 4.1b).  In the dominant negative Rac mutant stable cell lines, total 
Rac expression is again increased 2-fold over that of the control.  However, total Rac 
activity is greatly decreased in the mutant cell lines as compared to that of the vector 
control (Figure 4.1c). 
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Dominant active Rac mutants increase cell cycle progression. 
 Active Rac proteins can signal to the cell cycle promoters JNK, p38MAP kinase, 
and NFkB (Cotteret and Chernoff, 2002).  The ability of Rac to weakly transform cells is 
thought to be linked to these signal pathways (Westwick et al., 1997; van Leeuwen et al., 
1995).  Moreover, there is evidence to suggest that Rac3 is more efficient at promoting 
cell cycle progression than Rac1 (Mira et al., 2000).  Therefore, we performed cell cycle 
analysis on the stable Rac mutant cell lines. 
 Subsequent to analysis, we found that dominant active Rac1 or Rac3 can increase 
the percentage of cells in S phase over that of the control, indicating an increase in cell 
cycle progression (Figure 4.2).  However, dominant active Rac3 did not activate cell 
cycle progression more than dominant active Rac1, indicating little difference in the cell 
cycle promoters downstream of these two isoforms, or their ability to bind to them.  
Conversely, no difference was found between the percentage of cells in S phase of the 
dominant negative mutant stable cell lines and their control (Figure 4.3).  Even though 
Rac proteins can activate cell cycle promoters, their endogenous interaction is weak and 
the signaling inefficient (Cotteret and Chernoff, 2002).  Other proteins within the cell are 
better able to bind and active cell cycle signaling cascades, such as the map kinases 
signaling cascades (Cotteret and Chernoff, 2002).  Therefore, blocking Rac activation has 
little effect on cell cycle progression in vitro, suggesting that the involvement of Rac in 
metastatic progression includes downstream effectors not involved in cell proliferation.          
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Ectopic Rac(G12V) expression augments the invasive phenotype of low metastatic 
breast cancer cells. 
 Invasive malignant cell morphology includes an increased number of focal 
adhesions, as well as an increase in actin structures such as cross-linked actin fibers and 
membrane ruffles (Condeelis et al., 2001).  The morphology of the low metastatic cell 
variant MDA-MB-435Br1 when expressing vector alone is indicative of a less invasive 
cell.  Actin fibers are not cross-linked, lamellipodia are limited to the proximal and distal 
ends of the cell, and focal adhesions are few (Figure 4.4).  Conversely, MDA-MB-
435Br1 cells expressing myc-Rac1(G12V) or myc-Rac3(G12V) exhibit cross-linked actin 
fibers, numerous focal adhesions, and lamellipodia expressed ubiquitously around the 
periphery of the cell (Figure 4.4).  Expression of either myc-Rac1(T17N) or myc-
Rac3(T17N) in the highly metastatic MDA-MB-435α6HG6 variant exhibit a less 
dramatic morphology than the dominant active mutants (Figure 4.5).  Though, cells 
expressing Rac1(T17N) or Rac3(T17N) appear to exhibit smaller lamellipodia and less 
focal adhesions per cell than the vector control. 
  
Rac mutants significantly alter cellular processes essential to metastatic behavior. 
 Because metastatic progression results from increased migration of malignant 
cells out of the basal lamina, subsequent adhesion to the extracellular matrix, and final 
invasion into distant tissues to establish secondary sites of metastasis, we measured the 
effect of Rac mutants on these processes in vitro.  For each of these assays, cells 
expressed equal amounts of activated Rac1 or Rac3 mutant protein (Figure 4.1). 
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Recent data indicate that changes in cell adhesion play a critical role in tumor 
progression (Cavallaro and Christofori, 2004); thus, we tested the ability of Rac mutants 
to alter adhesive properties of malignant cells in vitro.  Dominant active Rac1(G12V) or 
Rac3(G12V) cause a significant increase in adhesion to basal lamina when expressed in 
low metastatic MDA-MB-435Br1 as compared to the vector alone control, while 
dominant negative Rac1(T17N) or Rac3(T17N) cause a significant decrease in adhesion 
when expressed in high metastatic MDA-MB-435α6HG6 (Figure 4.6a, 4.7a).   
A requirement of malignant cells to undergo metastasis is the acquisition of the 
ability to penetrate surrounding ECM proteins in order to migrate to distant tissues 
(Playford and Schaller, 2004); thus, we tested the effect of Rac mutants on both migration 
and invasion in vitro.  Both myc-Rac1(G12V) and myc-Rac3(G12V) caused a significant 
increase in migration and invasion when expressed in the low metastatic variant (Figure 
4.6b,c). Surprisingly, myc-Rac3(G12V) expressing cells invaded through basal lamina 
1.5 times more than cells expressing Rac1(G12V) (Figure 4.6c).  Invasion of high 
metastatic cells expressing dominant negative Rac1(T17N) or Rac3(T17N) was 
significantly diminished as compared to the vector alone control (Figure 4.7c).  
Furthermore, migration was also significantly reduced in highly metastatic cells 
expressing dominant negative mutants of Rac isoforms as compared to vector control 
(Figure 3.8c).  Therefore, Rac activity is directly involved and necessary for increased 
migration during the invasion of metastatic breast cancer cells.  Taken together, this data 
establishes the efficacy both Rac1 and Rac3 in metastatic processes. 
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Rac mutants alter pulmonary metastasis in vivo.   
 The mouse model of experimental metastasis is an assay used to determine the 
effects of stable cell lines on the process of metastasis in vivo.  Once injected into the 
mammary fat pad of immunocompromised mice, human mammary cancer cells must 
form a primary tumor, migrate away from the primary tumor, travel through the blood 
stream, exit the blood stream and form a secondary, metastatic, tumor at a distant site.  
Therefore, the stable cell lines expressing mutant forms of Rac isoforms, as well as their 
vector controls, were tested in this model. 
 Injection of stable cell lines expressing dominant active forms of Rac1 or Rac3 
promoted pulmonary metastasis as compared to the control.  Once the primary tumors 
had reached 1-1.5 cm in diameter, the lungs were assayed for pulmonary metastases.  The 
vector alone control cell lines MDA-MB-435Br1 never exhibited pulmonary metastasis, 
as the excised lungs demonstrated no lesions in any of the lobes (Figure 4.8a).  Both of 
the mutant Rac cell lines were able to contribute to lung metastases, as the excised lungs 
exhibited numerous lesions in all three lobes (Figure 4.8b,c).  Subsequent to quantitation, 
MDA-MB-435Br1Rac1(G12V) exhibited an average of 28 pulmonary lesions, with an 
average volume of 3.6 mm3.  MDA-MB-435Br1Rac3(G12V) exhibited an average of 14 
pulmonary lesions, with an average volume of 1.71 mm3.  Therefore, both Rac1 and Rac3 
can contribute to breast cancer metastasis in vivo.   
 Injection of stable cell lines expressing dominant negative Rac1 or Rac3 blocked 
pulmonary metastasis as compared to the vector alone control (Figure 4.9).  Moreover, 
dominant negative Rac1 or dominant negative Rac3 appeared to slow the primary tumor 
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growth in vivo (Figure 4.9).  Primary tumors formed by the injection of cell lines 
expressing Dominant negative Rac1 averaged 50 mm3, while those formed by the 
injection of cell lines expressing dominant negative Rac3 averaged 100 mm3.  The 
average primary tumor formed by the vector alone control was 300 mm3.  Furthermore 
the vector alone control, MDA-MB-435a65HG6, exhibited several pulmonary 
metastases, while the dominant negative Rac isoforms did not (Figure 4.9).  On average, 





In this study we demonstrate, for the first time, the efficacy of both the Rac1 and 
Rac3 isoforms in the malignant progression of human breast cancer.  Because Rac1 and 
Rac3 both have been implicated in breast cancer (Leung et al., 2003; Bouzahzah et al., 
2001), we carried out a comparative study between the two isoforms.  Activation of the 
Rac1 or Rac3 isoforms in a transformed cell with a non-invasive morphology drastically 
changes the invasive actin structures and increases the number of focal adhesions. 
Activation of Rac1 or Rac3 also causes an increase in cell cycle progression in low 
metastatic breast cancer cells.  Additionally, we found that blocking Rac activity by 
expressing dominant negative mutations of Rac1 or Rac3 significantly curtailed cellular 
processes critical for metastatic progression in vitro.  Moreover, we found that 
augmenting endogenous Rac activity by expressing dominant active Rac1 or Rac3 led to 
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a significant increase in adhesion, migration, and invasion.  Taken together, these data 
substantiate not only a vital role for Rac1 in breast cancer metastasis, but also a vital role 
for Rac3, for the first time.  In fact, expression of a dominant active Rac3 in the MDA-
MB-435Br1 low metastatic cell variant increased invasion through basal lamina 1.5 times 
as compared to expression of dominant active Rac1.  This difference suggests an 
enhanced ability of the cells expressing Rac3(G12V) to degrade the extracellular matrix, 
allowing for invasion, as compared to the cells expressing Rac1(G12V).  It is possible 
that Rac3 is more efficient at activating proteins that degrade extracellular matrix 
proteins, or matrix metalloproteinases (MMPs), than is Rac1.  Because our in vitro data 
was convincing of a role for Rac3 in human breast cancer metastasis, we took an in vivo 
model approach:  the nude mouse model of experimental metastasis. 
 
Justification of the Nude Mouse Model of Experimental Metastasis  
In vitro assays modeling invasion, adhesion, and migration are extremely limiting 
in their ability to mimic all aspects of metastatic progression.  Recently, the idea of the 
tissue surrounding tumor cells, or the tumor microenvironment, playing a decisive role in 
triggering invasion has begun to receive increased attention (Quaranta and Gianelli, 
2003).  These in vitro assays that measure individual aspects of cell invasion fail to 
include the tumor microenvironment, which can contribute substantially to the metastatic 
process.  The only way to  mimic the tumor microenvironment is to use an animal model 
that closely shares human characteristics (Khanna and Hunter, 2005).  The mouse model 
of experimental metastasis is the most common in vivo model used to mimic human 
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cancer progression.  This model is the closest mimic to human cancer progression 
because it includes the delivery of cancer cells to the anatomic location or tissue from 
with the tumor was derived (orthotopic transplantation).  Orthotopic transplantation has 
been shown to result in tumor models that more closely resemble human cancers with 
respect to tumor histology, vascularity, gene expression, responsiveness to chemotherapy, 
and metastatic biology (Bibby, 2004; Khanna, et al., 2000). 
 However, there are limitations to this model.  For example, tumorigenesis is not 
only the result of uncontrolled proliferation of a mutated cell, but it is a complex 
interaction between the tumoregenic tissue and the environmental tissue in which it arises 
(Quaranta and Gianelli, 2004).  In our system, we are implanting human cells in mouse 
tissue.  Because of the discrepancy between the two species, this tumor implantation may 
not recapitulate all interactions between the neoplastic cells and tumor microenvironment 
essential to the process of human tumor dissemination.  Additionally, mechanical 
disruption of the area affected by the implantation itself may permit tumor cells to 
disseminate directly into the circulatory system, bypassing invasion into the surrounding 
tissue altogether (Khanna and Hunter, 2005).  Finally, orthotopic injection of genetically 
engineered cells into the mouse model is limited by its reliance on cultured cells.  
Cultured cells used in spontaneous mouse models of cancer have been adapted for years 
to grow in two-dimensional matrix platforms, which create adaptations that are foreign to 
a three-dimensional system (Khanna and Hunter, 2005).  The adaptations that allow cells 
to grow in culture may alter the pathways by which endogenously arising metastasis 
survive.  Clearly, the mouse models have their limitations.  Therefore, a multi-faceted 
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approach to studying metastatic progression, one which includes an in vitro component as 
well as an in vivo approach, was taken. 
 
In vivo Data from Animal Models 
However, when comparing Rac1 with Rac3 in the animal models, it appears that 
Rac1 is more efficient at promoting metastasis than is Rac3.  The cell lines expressing a 
dominant active Rac1 promoted the formation of more pulmonary metastases with larger 
volumes than the cell line expressing a dominant active Rac3.  Moreover, blocking Rac 
activity caused smaller primary tumors to form in the marine mammary fat pad than 
blocking Rac3.  This result is in contrast to our cell cycle data, which showed no 
difference in cell cycle progression between the cell line blocking Rac1 activity and the 
cell line blocking Rac3 in culture.  Perhaps the murine model is a better measure of how 
cells will behave in vivo.  Cells encounter a much different, 3-dimensional environment 
in vivo than in vitro.  More and more data is beginning to indicate that the tumor 
microenvironment is equally as important as the cellular make up of the tumor in 
predicting invasive behavior (Quaranta and Giannelli, 2003).  In addition to responding to 
the composition of the substratum, cells sense and react to physical properties that 
include 3-dimensionality and the rigidity of the matrix (Yamada et al., 2003).  Moreover, 
the molecular composition of focal adhesions that cells form in 3-dimensional matrices 
are very different than those formed in more traditional, 2-dimensional matrices 
(Cukierman et al., 2001; Yamada et al., 2003).  Additionally, cells show more rapid 
morphological changes, migration, and proliferation in 3-dimenstional matrices compared 
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to standard 2-dimensional matrices (Yamada et al., 2003).  Therefore, models that mimic 
the true microenvironment are becoming increasingly important when trying to predict 
the outcome of tumor invasion.  
Our in vivo data point to the conclusion that Rac1 is more efficient at both 
promoting growth and increasing metastasis in the murine model.  Rac1 and Rac3 differ 
in their C-terminus region which is essential for subcellular localization (Haataja et al., 
1997).  Even though protein function is likely partially redundant due to the homology of 
the downstream effector loops, these proteins have been found to differ in their 
localization within certain types of cells (Bolis et al., 2003).  Differential subcellular 
localization can place proteins in the proximity of different signaling cascades, resulting 
in differential function.  However, more experiments are needed to show that Rac1 
actually acts differently than Rac3 with respect to human breast cancer.  For example, 
creating stable knockdowns with siRNA would be an extremely valuable tool to elucidate 
the functions of Rac3 that differ from the functions of Rac1.  By using dominant active 
mutations of isoforms that are so closely related, the possibility that downstream effectors 
are cross-activated is very likely.  The same is true for the dominant negative mutants.  
Our approaches in this research are somewhat limited, and there are many future 
experiments that should be considered with regard to differential Rac1 and Rac3 




In conclusion, our data strongly suggests that both Rac1 and Rac3 are important 
for the metastatic phenotype of human breast cancer.  By using variants of the same cell 
line, we have minimized genetic variation.  Because of the similarity of the genetic 
background of these variants, Rac activity differences were striking, and very suggestive 
of an essential role for this subfamily of proteins in the metastatic progression of human 



























































Figure 4.1.  Characterization of stable cell lines expressing mutant Rac isoforms.   
 
Whole cell lysates of all stable cell lines (a) were subjected to SDS-PAGE followed by 
western blot analysis for total Rac using an anti-Rac antibody.  Dominant active cell lines 
are shown in (b), dominant negative cell lines are shown in (c).  Rac activity was assayed 
using the PAK-PBD activity assay.  Equal loading of lanes was maintained by 
performing a total protein assay and is confirmed by western blot analysis for total actin.  





























                        Rac1(G12V)                                        Rac3(G12V) 
 
Figure 4.2  Cell cycle analysis of stable cell lines expressing vector alone, dominant 
active Rac1, or dominant active Rac3.  Vector alone (a), dominant active Rac1 (b), or 
dominant active Rac3 (c) stable cell lines were fixed, stained with PI, and subjected to 
flow cytometry.  S phase is the peak between G1 and G2 phases, and is representative of 
cell cycle progression.  MDA-MB-435Br1 Vector alone S phase is 43.5% of all cells 
assayed; MDA-MB-435Br1Rac1(GV) S phase is 50.4% of all cells assayed; MDA-MB-





























                               Rac1(T17N)                                     Rac3(T17N) 
 
Figure 4.3  Cell cycle analysis of stable cell lines expressing vector alone, dominant 
negative Rac1, or dominant negative Rac3.  Vector alone (a), dominant negative Rac1 
(b), or dominant negative Rac3 (c) stable cell lines were fixed, stained with PI, and 
subjected to flow cytometry.  S phase is represented by the peak between G1 and G2 
phases, and is representative of cell cycle progression.  MDA-MB-435a6HG6 vector 
alone S phase is 43.9% of all cells assayed; MDA-MB-435a6HG6Rac1(TN) S phase is 
45.4% of all cells assayed; MDA-MB-435a6HG6Rac3(TN) S phase is 40.9% of all cells 
assayed.       
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Figure 4.4.  Effects of ectopic dominant active Rac(G12V) expression in low 
metastatic variant MDA-MB-435Br1 on cellular morphology.  Confocal DIC and 
fluorescent microscopy were performed on MDA-MB-435Br1 cell variant stably 
expressing vector alone, myc-Rac1(G12V), or myc-Rac3(G12V).  Cells were plated on 
glass coverslips, fixed in 3.7% formaldehyde and permeabilized with 0.2% Triton X-100.  
Actin was then visualized with rhodamine phalloidin and focal adhesions were visualized 


































Figure 4.5.  Effects of ectopic dominant negative Rac(T17N) expression in highly 
metastatic variant MDA-MB-435a6HG6 on cellular morphology.  Fluorescent 
microscopy was performed on the MDA-MB-435a6HG6 cell variant stably expressing 
vector alone, myc-Rac1(T17N), or myc-Rac3(T17N).  Cells were plated on glass 
coverslips, fixed in 3.7% formaldehyde and permeabilized with 0.2% Triton X-100.  
Actin was then visualized with rhodamine phalloidin and focal adhesions were visualized 
























Figure 4.6.   Effects of dominant active Rac isoforms on metastatic properties, as 
measured in vitro.  MDA-MB-435Br1 cells expressing vector alone, myc-Rac1(G12V), 
or myc-Rac3(G12V), were subjected to adhesion (a), haptotaxis (b), and invasion (c) 
assays.  Cells were counted under (200X) for adhesions assays, and (400X) for haptotaxis 
and invasion assays.  Y-axis represents the number of cells/field for at least 20 
microscopic fields per cell line.  Bars represent standard error of the mean, and is 
representative of at least 3 separate experiments.  An asterix  indicates a statistically 
significant difference compared to the control, vector alone, as determined by a Student’s 







Figure 4.7.   Effects of dominant negative Rac isoforms on metastatic properties, as 
measured in vitro.  MDA-MB-435α6HG6 cells transiently expressing vector alone, myc-
Rac1(T17N), or myc-Rac3(T17N), were subjected to adhesion (d), and invasion assays 
(e).  Cells were counted at (200x) for adhesions assays, and (400x) for haptotaxis and 
invasion assays.  Y-axis represents the number of cells/field for at least 20 microscopic 
fields per variant.  Bars represent standard error of the mean, and is representative of at 
least 3 separate experiments.  An asterix  indicates a statistically significant difference 
compared to the control, vector alone, as determined by a Student’s t-test (P<0.05).  
(Migration of cells expressing dominant negative Rac isoforms was shown in Chapter 3, 
figure 3.8.)  
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Figure 4.8.  Effects of dominant active Rac isoforms on pulmonary metastasis, as 
measured in vivo.   Representative appearance of murine lungs where metastasized 
colonies are visible as white foci 3-4 months subsequent to fat pad injection.  (a) MDA-
MB-435Br1 vector control, (b) MDA-MB-435Rac1(G12V), (c) MDA-MB-



















Figure 4.9.  Effects of dominant active Rac isoforms on pulmonary metastasis, as 
measured in vivo.   (a)  Lesion number is lungs was counted, and Rac(G12V) expressing 
cells show an increase in colony formation.  (b)  Average pulmonary lesion size, as 












Figure 4.10.  Effects of dominant negative Rac isoforms on primary tumor size, as 
measured in vivo.  Cell lines expressing dominant negative Rac constructs reduced the 
size of the primary tumor formed, as compared to vector alone 15 weeks subsequent to 




















































Figure 4.11.  Effects of cells expressing dominant negative Rac isoforms on 
pulmonary metastasis, as measured in vivo.  (a)  Cell lines expressing dominant 
negative Rac 1 or 3 constructs blocked metastatic lung tumor formation, as compared to 
the vector control 15 weeks subsequent to fat pad injection.  (b)  Average pulmonary 










Overview:  Metastasis Regulators in Human Breast Cancer 
The foremost goal of the research presented here is the elucidation of proteins 
capable of either inducing or negatively regulating breast cancer metastasis.  As 
mentioned earlier, cancer not only presents an interesting molecular mechanism 
challenge, but it also presents a terrible and debilitating disease.  Furthermore, cancer has 
seen less success in the advancement of treatment over the past 50 years than heart 
disease, cerebrovascular disease, and pneumonia, diseases which are considered the most 
deadly diseases in the US (ACS, 2005).  Breast cancer is the leading type of cancer 
occurring in women in the US, and it is estimated that one in eight women will develop 
breast cancer, and of these women, 30% will die from metastatic progression (Bowcock, 
1999).  Therefore, it is essential to elucidate the mechanisms by which breast cancer 
metastasizes in order to prevent further mortality. 
To date, there are very few bona fide “metastasis suppressors”, and even fewer 
metastasis suppressors specifically related to breast cancer (Keller, 2004).  Of these genes 
regarded as possible metastasis suppressors in breast cancer, few have been thoroughly 
investigated.  Most evidence is based on expression patterns in non-invasive versus 
invasive tissue samples from breast biopsies and tissue aspirations (Jiang et al., 2004; 
Steeg et al., 2003).  Our approach is to use this data, but apply techniques of protein 
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biochemistry and cell biology to elucidate the mechanisms of the candidate proteins in 
order to pinpoint specific protein interactions that inhibit or upregulate breast cancer 
metastasis.  The prevalent thought in the field of metastasis suppressors is that an 
improved molecular and biochemical understanding of the metastatic process is expected 
to fuel the development of new therapeutic approaches (Steeg et al., 2003).  These new 
therapeutic approaches are, unfortunately, sorely needed.  
The idea of metastasis suppressors as therapeutic targets could involve the 
restoration of a metastasis suppressor gene or the inhibition of a metastasis inducer gene, 
to the extent that it could interrupt a facet of the metastatic cascade and produce a clinical 
benefit. Anti-cancer drug development is currently based on in vivo models of 
tumorigenecity, including assays with immunocompromised mice.  Our approach is to 
use current models of metastasis assays with immunocompromised mice to demonstrate 
the efficacy of candidate metastasis suppressors or metastasis inducers in vivo.  Our hope 
is that the information presented in this research can be used to develop novel treatments 
for patients with metastatic breast cancer.     
Recent data indicates strongly that growth at a primary tumor site and growth at a 
metastatic site differ by the expression and/or context-dependent function of the 
metastasis regulator, and that a wide variety of signaling pathways are affected (Steeg et 
al., 2003).   Data presented here argues a strong case for PTEN as a metastasis suppressor 
and Rac proteins as metastasis inhibitors, for the fact that they fit the criteria.  PTEN 
expression has been shown to be inversely correlated with increasing metastatic potential 
in a variety of human breast tumors (Lee et al., 2004).  Furthermore, PTEN negatively 
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regulates PIP3.  PIP3 is a second messenger that regulates a myriad of signaling 
pathways, including those involved in cell survival, cell cycle progression, as well as cell 
migration and invasion (Rameh and Cantley, 1999).  Additionally, Rac expression has 
been shown to be correlated with increasing metastatic potential in a variety of human 
tumors (Fritz et al., 1999).  Rac activation can also regulate numerous signaling 
pathways, including those involved in cell survival, cell cycle progression, as well as cell 
migration and invasion (Etienne-Manneville and Hall, 2002).  Our data makes a 
convincing case that PTEN curtails migration in metastatic human breast cancer cells.  
Our data also demonstrates that in an in vivo model, Rac proteins can promote tumor 
metastasis when activated, and block tumor metastasis when inhibited.  Taken together, 
these data support the usefulness of the PTEN protein and the Rac proteins in possible 
metastasis therapeutics for breast cancer.    
 
Direct Implication of Rho GTPases in Metastatic Human Breast Cancer 
 The data presented here, for the first time, directly implicate the Rho GTPases 
Rho, and Rac in the progression of human breast cancer metastasis.  A range of cell 
variants, varying in their metastatic potential to metastasize in the nude mouse model of 
experimental metastasis, were derived from the same parental cell lines, MDA-MB-435 
(Mukhopadhyay et al., 1999).  We used this panel of metastatic variants to identify 
differential protein expression and activity.  This panel gives us a powerful tool to study 
the regulators of metastasis in that all cell included in the panel have very similar genetic 
profiles.  Most studies before using a “range” of cell lines differing in metastatic potential 
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have used cell lines cloned at different times from different patients.  This variety 
introduces errors, due to extensive differences in the genetic profiles of these cells.  
Because our panel was derived from the same parental line, we have a powerful tool to 
study those proteins both causal and inhibitory specifically in relation to breast cancer 
metastasis.     
It is generally agreed that an improved molecular and biochemical understanding 
of the metastatic process is expected to fuel the development of new therapeutic 
approaches (Steeg et al., 2003).  Recent data indicate strongly that growth at a primary 
tumor site and growth at a metastatic site differ by the expression and/or context-
dependent function of the metastasis regulator (Steeg et al., 2003).  Additionally, proteins 
identified as metastasis regulators would be involved in numerous signaling pathways, 
including those important for primary tumorigenesis, as well as metastatic progression.  
Rho GTPases fit all of these criteria.  Rac and Cdc42 GTPases regulate motility via PAK, 
and Arp2/3 via WASP and WAVE (Etienne-Manneville and Hall, 2002).  These proteins 
also regulate cell cycle progression and cell survival via NFkB, MEKK, MLK, as well as 
stress-activated p38 MAP kinases (Cotteret and Chernoff, 2002).  In fact, Rac3 was found 
to have a significant impact on the proliferation of breast cancer cells (Mira et al., 2000).  
RhoA and C proteins also regulate motility via mDia (stress fiber formation) and ROCK 
(acto-myosin contraction).  Therefore, Rho GTPases become ideal candidates for 




Direct role for Rac3 in metastatic human breast cancer   
The data presented here, for the first time, directly implicate the recently cloned 
Rho GTPase protein Rac3 in the metastatic progression of human breast cancer.  A 
comparative study between two isoforms of Rac, Rac1 and Rac3, was carried out due to 
the fact that both isoforms have been implicated in breast cancer tumorigenesis (Leung et 
al., 2003; Bouzahzah et al., 2001).  What has not been addressed, however, is the 
possibility of a role for Rac3 in breast cancer metastasis.  Recent data has shown a 
specific role for Rac3 in the hyperproliferation of breast cancer cells, as well as the ability 
of Rac3 to promote primary mammary lesions in mice (Mira et al., 2000; Leung et al., 
2003).  The study presented here, however, is novel in that we substantiate a role for 
Rac3 in human breast cancer progression to the metastatic state.     
In summary, we found that blocking Rac activity by expressing dominant 
negative mutations of Rac1 or Rac3 significantly curtailed cellular processes critical for 
metastatic progression in vitro.  Moreover, we found that augmenting endogenous Rac 
activity by expressing dominant active Rac1 or Rac3 led to a significant increase in 
adhesion, migration, and invasion.  Taken together, these data substantiate not only a 
vital role for Rac1 in breast cancer metastasis, but also a vital role for Rac3, for the first 
time.  In fact, expression of a dominant active Rac3 in the MDA-MB-435Br1 low 
metastatic cell variant increased invasion through basal lamina 1.5 times as compared to 
expression of dominant active Rac1.  This difference suggests an enhanced ability of the 
cells expressing Rac3(G12V) to degrade the extracellular matrix, allowing for invasion, 
as compared to the cells expressing Rac1(G12V).  It is possible that Rac3 is more 
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efficient at activating proteins that degrade extracellular matrix proteins, or matrix 
metalloproteinases (MMPs), than is Rac1.  Most significantly, however, we found that 
blocking Rac3 activation could block metastasis in an in vivo model.  Additionally, we 
found that activating Rac3 could promote metastasis in an in vivo model.  Taken together, 
these data cement a significant role for the Rac isoform Rac3 in human breast cancer 
progression. 
 
5.2 Future Experiments 
 
Investigation of a Role for RhoC in Breast Cancer Metastasis 
 The RhoA and RhoC genes are 92% identical (Ridley, 1997).  They are regulated 
in the same GDP/GTP cycle, and can be sequestered in the cytosol by RhoGDIs (Wheeler 
and Ridley, 2004).  No clear difference of the RhoGEFs Vav, p115RhoGEF, and Brc, or 
the Rho GAP p190RhoGAP, in binding affinity between the two proteins (Wheeler and 
Ridley, 2004).  RhoA and RhoC have both been found to localize either in the cytosol or 
the plasma membrane (Wheeler and Ridley, 2004).  Rho effector proteins such as ROCK, 
mDia, Rhotekin, Rhophillin, and Citron Kinase have been found to interact with both 
isoforms (Wheeler and Ridley, 2004).  These findings suggest that there will be little 
difference between RhoA and RhoC function in vivo.    
 However, RhoA and RhoC do exhibit slight differences in sequence, which 
translate into substantial differences in function (Wheeler and Ridley, 2004).  Most 
divergence between the protein sequences is found at the C-terminus, but some 
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variability is found in the insert loop (Wheeler and Ridley, 2004).  These differences 
would indicate a difference in localization, and perhaps a difference (although not 
spectacular) in binding affinity to GTPase regulators.  While RhoA and RhoC expression 
have both been found to be upregulated in certain tumors, it appears that only RhoA can 
promote transformation of cultured fibroblasts (Wheeler and Ridley, 2004).  Recently, 
though, RhoC has attracted substantial interest with its increased expression being 
correlated to increased invasion in several types of cancers:  gastric, bladder, colon, 
breast, melanoma, and non-small-cell lung carcinoma (van Golen et al., 2000; Clark et 
al., 2000; Kamai et al., 2003; Shikada et al., 2003; Kondo et al., 2004; Frtiz et al., 1999).  
Other evidence indicates that RhoA impedes, while RhoC stimulates invasion (Simpson 
et al., 2004).  This difference could be due to the finding that RhoC binds with more 
affinity to ROCK than does RhoA (Sahai and Marshall, 2002).  ROCK is an important 
downstream effector of Rho proteins that activates cell contraction via phosphorylation 
and activation of myosin light chain (Riento and Ridley, 2003).  More contraction could 
lead to enhanced motility.  Additionally, RhoC siRNA has been shown to block breast 
cancer metastasis in vivo in the mouse model of metastasis (Pille et al., 2005).   
Herein, we show convincing evidence that RhoC plays an important role in the 
invasive and metastatic capability of human breast cancer progression.  RhoC is more 
highly expressed in the more metastatic cell variants, while RhoA expression is relatively 
equal.  Additionally, blocking RhoA has no effect on cell migration in the most migratory 
cell variant (MDA-MB-435α6HG6).  Future experiments include cloning the RhoC 
cDNA into a mammalian expression vector with antibiotic selection markers and site 
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directed mutagenesis to create the dominant negative mutant.  Subsequent to the 
generation of stable cell lines, analysis of blocking RhoC and the affect of that blockage 
on motility and invasion will be analyzed.  Finally, we would like to use the nude mouse 
model of experimental metastasis to test out hypothesis in vivo.           
 
Cross Talk between Rho GTPases in breast cancer 
 Rho GTPases have long been known to participate in cross talk (Burridge and 
Wennerberg, 2004).  However, the extent to which they do this and the implied 
physiological significance is still under investigation.  The activation of the Rho family of 
small GTPases, namely Rho, Rac, and Cdc42, is a critical event in the integrin-mediated 
regulation of the cellular processes of adhesion, migration, and invasion (Miranti and 
Brugge, 2002; Hynes, 2002).  During these processes, crosstalk between the Rho 
GTPases, their isoforms, and their downstream effectors are coordinated in a highly 
complex and not completely understood manner (Schmitz et al., 2000).  Activation of 
appropriate levels, together with temporal and spatial coordination, must be precisely 
regulated in order to achieve normal adhesion and motility (Price and Collard, 2001).  
The balance between Rho, Rac, and Cdc42, as well as the localized activity of these 
proteins, is essential for the determination of cellular morphology and invasive behavior 
(Evers et al., 2000). 
 A recently published study revealed a compensatory relationship between RhoA 
and RhoC at both expression and activation levels, and a reciprocal relationship between 
RhoA and Rac1 activation (Simpson et al., 2004).  This finding implies that one tumor 
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marker or metastasis marker is not enough to predict the outcome of tumor invasion.  For 
example, increased RhoA expression but decreased RhoC expression may indicate a 
tumor that is not extremely aggressive, while a tumor expressing elevated RhoC but 
decreased RhoA might present a more invasive phenotype. 
 Because we see elevated Rac activity and RhoC expression in the most highly 
metastatic variant, it would be interesting to investigate the interplay between these 
proteins.  I would hypothesize that expressing RhoA in the highly metastatic cell line 
would decrease invasiveness, which is a result contradictory to classical hypotheses and 
approaches.  Additionally, exploring the crosstalk between Rac3 and RhoC would be 
completely novel, based on the finding that Rac3 is important in cell proliferation (Mira 
et al., 2000).  Specifically, the approach to study crosstalk would rely on double mutant 
studies.  That is, expression of a dominant active RhoA and a dominant negative RhoC.  
Hypothetically, this expression would decrease both cell motility and Rac activation, 
while the reciprocal experiment (expression of dominant negative RhoA and dominant 
active RhoC), would result in increased motility and increased Rac activation.   It may 
become important in the future to know the mechanisms of crosstalk, for they may be 
useful to predict patient outcome. 
 
Elucidation of Rac1 versus Rac3-specific GEFs 
 Rac1 and Rac3 are 92% homologous (Haataja et al., 1997).  Yet, why would two 
proteins exist to function in exactly the same way in cells?  Some differences have been 
noted in expression and function between the two isoforms.  For example, Rac3 has been 
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found to be more highly expressed in neural tissue than is Rac1 (Bolis et al., 2003).  This 
differential distribution is thought to support a role for Rac3 specifically in the 
remodeling of Purkinje cell neuritic terminals at the time of synaptogenesis (Bolis et al., 
2003).  Rac3 has been found to interact with the integrin-binding protein CIB (calcium 
and integrin-binding), a protein with which neither Rac1 nor Rac2 interact (Haataja et al., 
2002).  This differential binding is thought to implicate Rac3 specifically in integrin-
associated cytoskeletal reorganization during αIIBβ3-mediated adhesion (Haataja et al., 
2002).  Furthermore, Rac3, but not Rac1, was found to control proliferation in breast 
cancer cells (Mira et al., 2000).   
 However, many similarities have also been noted.  The effector binding region in 
the Rac-like GTPases, or the switch region, is found to be 100% identical in Rac1 and 
Rac3 (Haataja et al., 1997).  This finding would indicate that Rac1 and Rac3 would bind 
the exact same downstream effectors.  Comparative functional analysis of the Rac 
GTPases indeed revealed that Rac1 and Rac3 exhibit consistent biochemical 
characteristics such as GTP hydrolysis and effector binding, and exhibited the same 
binding affinity for PAK (Haeusler et al., 2003).  Furthermore, studies that addressed Rho 
GTPase effect on the organization of the cytoskeleton found that expression of both Rac1 
and Rac3 resulted in the formation of lamellipodia (Aspenstrom et al., 2004).  However, 
these proteins differ in the amino acid sequence of their C-terminus, and are thus 
differentially prenylated (Joyce and Cox, 2003).  Differential prenylation indicates 
differential localization.  Rac1 and Rac3 also differ in their insert regions, which 
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influence interaction with guanine nucleotide exchange factors (GEFs) (Mira et al., 
2000).   
 Most GEFs contain a Dbl homology (DH) domain, which interacts with the 
effector domain (or switch region) of the small GTPase.  However, some (around 10) 
GEFs do not contain DH domains and therefore bind to the GTPase on other locations 
(Schmidt and Hall, 2002).  Evidence demonstrates that GEFs tightly bind to the effector 
domain, but interact with other domains in the protein structure (Schmidt and Hall, 2002).  
The insert region is one such region that binds regions of certain GEFs and determines 
binding affinity (Schmidt and Hall, 2002).  Because the insert region of Rac1 varies from 
that of Rac3, it is possible (and likely) that there are GEFs that preferentially bind one 
isoform over the other.  This is an area of study that needs to be addressed in the future. 
 To elucidate differential GEF binding, we plan to use the stable cell lines created 
earlier that express the dominant negative Rac1 or Rac3 isoforms.  Because the dominant 
negative isoforms are always in the inactive state, or constitutively bound to GDP, we 
hypothesize that GEFs will preferentially bind proteins in this state and try to activate 
them.  However, this interaction will not be successful, creating an extension of the time 
period to which GEFs are bound to the GTPases.  Subsequent to expression of the Rac 
mutant isoforms, an anti-Rac1 or anti-Rac3 immunoprecipitation will be performed on 
the cell lysates.  Proteins from these immunoprecipitations will be elecrophoresed on 2-
dimensional gels.  Spots that differ between Rac1 immunoprecipitations and Rac3 
immunoprecipitations will be excised and subjected to matrix-assisted laser 
desorption/ionization in a time-of-flight instrument (MALDI-TOF spectrometry).  This 
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procedure will determine if there are any differences in GEF binding, and which GEFs 




In summary, the research presented here encompasses several aspects of cancer, 
cell, and molecular biology.  Firstly, this research is important to the fields of cell 
signaling and cell biology.  Signaling aspects of the Rho GTPases, as well as 
PTEN/PIP3/FAK interactions are addressed and explored.  Additionally, the cellular 
processes of adhesion, cell migration, and invasion are investigated and their relation to 
signaling and implications for cancer metastasis are considered.  Finally, this research 
makes a significant contribution to the field of cancer biology.  Because of the necessity 
for more efficient anti-cancer therapies, it is essential to focus on basic science to identify 
molecular resources that can be tapped for better treatments.     
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